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ABSTRACT 
DEEPAK GOPALAKRISHNA: DiGeorge Syndrome phenotypes reflect disrupted 
interaction between inductive signals and 22q11 genes 
(Under the direction of Anthony LaMantia) 
 
We asked whether similar phenotypes that result from diminished 22q11 
gene dosage and altered Sonic Hedgehog (Shh), Fibroblast Growth Factor (Fgf), 
Retinoic Acid (RA) or Bone morphogenetic protein (Bmp) signaling reflect 
interactions between 22q11 genes and these cardinal morphogenetic signals. 
When Shh, RA, Fgf, or Bmp signaling is disrupted, expression levels, but not 
patterns, of several 22q11 genes change in mid-gestation mouse embryos, with 
most substantial changes associated with altered Shh signaling. When 22q11 
gene expression is diminished in mouse embryos by a deletion similar to that in 
DiGeorge/22q11 Deletion Syndrome (22q11DS), expression of a subset of Shh-, 
RA-, and Bmp-, but not Fgf-related signaling molecules is altered, with several 
RA intermediates most substantially changed. Shh and RA signaling, quantified 
using reporter mice, is altered in the brain or heart of 22q11 deleted, but not 
Tbx1+/-embryos, even though diminished Tbx1 dosage has been suggested as 
essential for 22q11DS phenotypes. Brief pharmacological disruption of Shh 
signaling in mid-gestation 22q11-deleted or wild type, embryos leads to severe 
dysmorphology. Disrupted RA signaling introduces or enhances brain and heart 
phenotypes in 22q11-deleted but not wild type or Tbx1+/- embryos. Thus, early 
	   iii	  
heart and brain morphogenesis depends on interactions between Shh and RA 
signaling and 22q11 gene dosage. Apparently, 22q11 gene dosage sustains 
normal morphogenesis by maintaining a dynamic range of signaling that, when 
altered, may intensify cardiovascular and CNS phenotypes in 22q11DS.  
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CHAPTER 1 
INTRODUCTION - I 
 
Patients with a heterozygous deletion of 30-40 genes on chromosome 22 
(22q11 deletion syndrome) exhibit significant variability of cardiovascular and 
brain phenotypes. This dissertation will focus on the analysis of the genetic, cell 
biological and molecular mechanisms of variability in the abnormal heart and 
brain development associated with 22q11 deletion syndrome. 
22q11Deletion Syndrome: consistent genetic cause and variable phenotypes 
22q11 deletion syndrome [DiGeorge syndrome (1)/ Velo-cardio-facial 
syndrome (2): 22q11DS] is the consequence of a hemizygous microdeletion on 
the proximal portion of the long arm of human chromosome 22. 22q11DS is the 
most common (1:2000) multiple anomaly syndrome resulting from copy number 
variation in humans (3, 4). The resulting wide spectrum of anomalies is due to a 
change in dosage of multiple syntenic genes as opposed to rare recessive single 
gene mutations or larger scale chromosomal rearrangements. This makes 
22q11DS an ideal model system to study the role of gene networks and gene 
dosage in early morphogenesis of various embryonic structures. Approximately 
~90% of 22q11DS patients have a similar 3 Mb (million base pair) deletion within 
the 22q11.2 region (5, 6) which contains about 40 genes (between LCR-A and 
LCR-D; Figure 1). A smaller percentage (8%) of patients carry a nested 1.5 Mb 
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deletion, spanning 30 genes (LCR-1 to LCR-B; Figure 1). Loss of the critical 
(1.5Mb) region seems to be sufficient to recapitulate penetrance and severity of 
the phenotypes resulting from the loss of the larger 3Mb region. Similar 
phenotypes resulting from non-overlapping deletions within the 22q11 region 
indicate that no single gene in the region is fully responsible (7, 8). In addition, 
there have been no single heterozygous gene mutations within the 22q11 region 
that have a similar phenotypic profile to the full deletion (Figure 1 – Indiv K/O). 
Thus, studying a contiguous gene syndrome like 22q11DS, whose genomic lesion 
and range of developmental phenotypes can be modeled in mice, will allow 
mechanistic molecular insight into multigenic networks of gene interactions that 
are disrupted in a variety of congenital developmental defects. I have used 
mouse models of 22q11DS to elucidate the interactions between the multigenic 
genomic lesion and M/E signaling that are disrupted in 22q11DS resulting in 
altered tissue morphogenesis. 
22q11DS is characterized by a spectrum of phenotypes in multiple organ 
systems whose early embryonic development is driven by mesenchymal-
epithelial interactions (M/E interactions). Common—and clinically significant—
manifestations of the disorder include craniofacial (cleft palate, velo-pharyngeal 
insufficiency), cardiovascular anomalies, immunodeficiency (thymic aplasia), 
short stature and hypocalcaemia (4, 9, 10). The syndrome has also drawn 
considerable attention because of its association with number of cognitive and 
behavioral impairments including attention deficit disorder, autism, 
schizophrenia, and bipolar disorder (11, 12). None of these individual features or 
phenotypes occurs with 100% penetrance, however, over 80% of all 22q11DS 
patients have some form of cardiovascular deficits and even more (>90%) exhibit 
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some form of cognitive and behavioral deficit. About 50% of these cardiovascular 
defects are classified under Tetralogy of Fallot, which consists of 4 defects 
(ventricular septal defects, narrowing of outflow tract, aorta that grows from 
both ventricles and right ventricular hypertrophy). The remaining 50% of cardiac 
defects are split between individuals who only have ventricular septal defects 
and individuals who have more severe outflow tract defects (10). The psychiatric 
defects range from mild ADHD or learning disabilities to severely disabling 
autistic spectral disorders and schizophrenia (35%). It is likely that this 
variability reflects a multilevel interaction with the signaling networks that 
provide the specification and differentiation cues to these morphogenetic 
domains. Thus, I have characterized molecular interactions between multiple 
genes in the 22q11 region and cardinal M/E signaling mechanisms in patterning 
the pharyngeal and forebrain morphogenetic domains.  
M/E inductive signaling and its role in 22q11DS phenotypic variation 
The most anterior portion of the neural tube, the telencephalon, gives rise 
to the cerebral cortex and its substructures including the forebrain (disrupted in 
22q11DS). The development of the forebrain is governed by critical M/E 
interactions between signaling from the surface ectoderm, genes and signals 
expressed in the mesenchyme (mainly neural crest derived) and the developing 
neuroepithelium of the telencephalic vesicles (Figure 2). The major structural 
defects in the heart and aorta/outflow tract are all derived from the pharyngeal 
apparatus, a temporary embryological structure that is caudal and lateral to the 
developing head (13). It consists of a series of segmented bulges on the lateral 
aspect of the embryo. Each pharyngeal arch is covered externally by epithelial 
tissue (ectodermal in origin) and contains a mesenchymal core that consists of a 
	   4	  
large population of neural crest cells (which delaminate from the ectodermally-
derived neural tube) and endodermally-derived mesenchymal cells (Figure 3). 
Similar to the forebrain, pharyngeal development and morphogenesis is driven 
by molecular interactions between the mesenchymal and epithelial (M/E 
interaction) structures of the pharyngeal pouches. Thus, M/E interactions are a 
shared morphogenetic mechanism that might be compromised in parallel in the 
brain and heart in 22q11DS. I will attempt to delineate any parallel or divergent 
nature of these interactions between 22q11 genes and multiple signaling 
networks. 
Clinical cardiovascular pathogenesis in 22q11DS ranges from the most 
frequent tetralogy of fallot (TF; 40%), truncus arteriosus (TA; 10%) and 
interrupted aortic arch (IA; 14%) to the less frequent double outlet right ventricle 
(DORV; 1%), transposition of the great arteries (1%) and patent ductus arteriosus 
(1%) (10, 14, 15). The pharyngeal apparatus gives rise to all the structures that are 
affected in 22q11DS. The pharyngeal endoderm forms the thyroid, parathyroid 
and thymus (16, 17) while the neural crest and cells of mesodermal lineage form 
the connective tissue, musculature, endothelial cells and skeletal tissue of the 
arch as well as its associated arteries (18-22). Multiple 22q11 genes are highly 
expressed in the neural crest cells as well as pharyngeal epithelium. Ablation of 
neural crest cells that migrate into the developing forebrain and pharyngeal 
region results in dysmorphology that is reminiscent of the defects seen in 
22q11DS (23, 24). Additional studies show that development of the arches 
depends on both crest-dependent as well as crest-independent cues (25, 26). The 
pharyngeal endoderm has surfaced as an important source of signaling 
molecules (27), Hox gene expression as well as an inducer of arch morphogenesis 
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(28-30). Thus, it is likely that diminished dosage of a large number of 22q11 genes 
in 22q11DS patients may disrupt morphogenetic function and identity of either 
the neural crest derived mesenchyme, the surface epithelium or both, altering the 
mesenchymal-epithelial (M/E) communication between the pharyngeal 
endoderm, mesenchyme and epithelium leading to disrupted pharyngeal 
morphogenesis. Thus I analyzed 22q11 gene distribution within each pharyngeal 
compartment and examined altered pharyngeal M/E signaling in a 22q11DS 
mouse model. 
Approximately 35% of 22q11DS patients are develop schizophrenia and a 
much larger percentage display other cognitive and behavioral deficits, including 
learning disabilities (67%), mental retardation (53%), autism (31%) and ADHD 
(16%) (11, 31). Given that specific regions and circuits are associated with these 
functions that are variably affected in 22q11DS, it is to be expected that patients 
with the deletion may have aberrant development of certain CNS structures that 
depend on M/E interactions. Indeed, children with 22q11DS seem to have 
altered grey and white matter volumes and exhibit enlargement of the lateral 
ventricles, the caudate and the insula (32). In contrast, the hippocampus and 
medial cerebellum are reduced in volume. There is also evidence of lateral 
thinning in parieto-occipital, occipital pole and inferior prefrontal regions, and 
medial thinning in anterior cingulate, medial frontal gyrus, subgenual prefrontal, 
posterior cingulate gyrus, cuneus and lingual gyrus regions in 22q11DS patients 
(33, 34). Few recent fMRI studies have also revealed atypical cortical activity 
during arithmetic and non-spatial working memory tasks (35, 36) in children 
with 22q11DS. Early brain development is highly integrated with the 
development of the face and jaw, as the same signals that pattern these external 
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structures also shape the development of midline patterning centers, the basal 
ganglia primordia and axonal inputs from the thalamus and brain stem. The 
cortex develops from a morphologically uniform ventricular zone located in the 
dorsocaudal part of the telencephalic vesicles. Cranial neural crest cells, derived 
from the dorsal mesencephalon and rhombencephalon, constitute a large part of 
mesenchymal tissue that lies adjacent to the developing brain (concentrated in 
anterior and ventral regions during early brain development) and acts as a 
signaling source. It is likely that diminished expression of 22q11 genes likely 
interferes with the ability of signaling centers to appropriately drive cortical 
morphogenesis. The range of phenotypes in 22q11DS indicates that gene dosage 
may be critical in these morphogenetic networks that drive remodeling of the 
brain. Thus, I will analyze the restricted expression of 22q11 genes in 
mesenchymal or epithelial compartments in the brain and heart and quantify any 
22q11-gene-dosage dependent M/E signaling with in these morphogenetic 
domains. Together, this data will provide insight into the role of 22q11 gene 
dosage in signaling networks that pattern and drive the development of the brain 
and heart.  
22q11DS phenotype: Variability and Phenocopies  
Even though most 22q11DS patients have the same 3 Mb deletion, the 
phenotype is highly variable (10). Early specification and patterning during the 
development of structures affected in 22q11DS is dependent upon FGF, RA, SHH 
and BMPs----signals whose activity is vulnerable to disruption by genetic and 
epigenetic variations. The cardiovascular phenotypes in 22q11DS range from 
mild disruptions to life threatening anomalies. As described above, the 
psychiatric and behavioral manifestations range from learning disabilities to 
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autism, psychosis, and mental retardation. The variable severity and penetrance 
of the cardiovascular, psychiatric and behavioral phenotypes in 22q11DS 
suggests that stochastic, environmental and genetic factors outside of the deleted 
22q11 locus likely modify the phenotypes. It has also been shown in mouse 
models that penetrance of the defects is highly dependent upon genetic 
background (37, 38). These findings suggest the presence of modifier genes 
elsewhere in the genome, perhaps on other chromosomes. Thus it is likely that 
signaling molecules are likely modifiers of the phenotypes. 
One way to identify candidate genes is to examine mouse mutants that 
carry null alleles that produce phenotypically similar defects to 22q11DS. SHH, 
RA, FGFs, BMPs and related signaling molecules have been proposed as likely 
candidates. Some phenotypes in mutant mice with disrupted Fgf8 (39) and RA 
(Raldh2) (40) signaling have been identified as 22q11DS “phenocopies”, while Shh 
(41) and Noggin/Chordin (Bmp signaling) anomalies (42) are more narrowly 
interpreted as “parallel” to 22q11DS. It is unclear whether such similarities 
reflect convergence of signals and 22q11 genes consistent with the strict 
definition of “phenocopy”, or instead, the phenotypic similarities are due to the 
influence of 22q11 genes and M/E signals on distinct aspects of development in 
similar tissues. My comprehensive expression analysis in signaling mutants and 
22q11DS mouse models will assess if the relationships between M/E signals and 
22q11 genes constitutes a strict phenocopy dogma or it reflects a network of 
interactions on multiple distinct levels.  
Shh 
Sonic hedgehog (SHH), a secreted, cholesterol-modified protein that binds 
to the transmembrane receptor Patched, activates intracellular GLI proteins, 
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allowing them to translocate into the nucleus and induce transcription of 
downstream targets (43). It is predominantly expressed in the pharyngeal 
endoderm in the heart and the ventral telencephalon and hypothalumus in the 
developing brain (44, 45). The Shh-/- mouse has a phenotype comparable to 
Tetralogy of Fallot with complete pulmonary atresia (41), indicating deficits in 
the secondary heart field, which gives rise to the outflow tract. Additional 
studies have shown that SHH is needed for neural crest cell survival as well as 
for the segmentation of the outflow tract (46). SHH-mediated proliferation in the 
second heart field is required for the formation of the myocardium and smooth 
muscle for the arterial pole and outflow tract (47). SHH is essential for the 
regionalization of the subpallium and also regulates morphogenesis and 
patterning of the pallium. Inactivation of Shh results in severe disruptions to 
midline formation and in particular for the formation of ventral brain structures 
(48) In addition to regulating cell fates during early neuronal specification, SHH 
has also been implicated in the proliferation of precursor cells in the CNS (49, 50) 
and granular cell precursors in the cerebellum during late embryogenesis (51-53). 
Thus, SHH’s important roles in processes that appear to be disrupted in 22q11DS 
(secondary heart field development and ventral pallial morphogenesis) indicate 
that the signal and several 22q11 genes may be involved in the same 
morphogenetic networks.  
RA 
During development Retinoic Acid (RA) serves as a ligand for nuclear 
receptors that regulate developmentally important genes. It influences the 
pattern formation of several structures including the brain and the heart (54-56). 
RA is primarily synthesized in the neural crest derived mesenchyme in the 
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pharyngeal apparatus and the ventrolateral mesenchyme of the developing 
forebrain (56, 57). Loss or gain of RA signaling by either genetic means or 
exposure to exogenous RA has severe consequences to embryonic development. 
Deletion of an RA synthetic enzyme Raldh2 results in a heart tube that fails to 
loop or form any posterior compartments. Mice carrying one hypomorphic allele 
and one null allele (Raldh2neo/−) display 22q11DS related thymic, parathyroid and 
cardiovascular defects including a persistent truncus arteriosus (PTA), 
ventricular septal defect (VSD) and aortic arch artery remodeling defects (40). 
Ablation of the RA receptors (RARa and RARb) results in exencephaly, 
underdeveloped telencephalic vesicles and abnormal frontonasal development 
(58). Deletion of a RA metabolizing enzyme, Cyp26a1, results in severe 
posteriorization of the embryo and disrupts rhombomere identity and in turn 
neural crest cells that contribute to forebrain development (59). Given its role in 
the development of the forebrain and heart structures that are also disrupted in 
22q11DS, and its activity in 22q11-gene expressing tissue, it is likely that RA may 
interact with 22q11 genes during cardiovascular and forebrain morphogenesis. 
FGF’s 
FGF8, a receptor-tyrosine-kinase signaling molecule, has a number of roles 
throughout heart and brain development. In the heart it is expressed in the 
pharyngeal endoderm and signals to the adjacent pharyngeal mesoderm and in 
the developing brain it is expressed at the rostral margin of the telencephalon. 
Fgf8-null mice have early heart looping abnormalities (60) while the Fgf8 
hypomorphs develops double outlet right ventricle, persistent truncus arteriosus, 
and has disrupted pharyngeal arch artery patterning (39). Thus, heart 
development is sensitive to FGF8 dosage. In Fgf8 deficient embryos, 22q11-gene 
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expressing cardiac neural crest cells die en route to and within the pharyngeal 
arches. Thus, FGF8 is necessary for 22q11-gene expressing neural crest cells to 
reach the pharyngeal arches and function normally in the septation of outflow 
tract (61). There is similar dose-dependency in the developing brain. FGF8 
promotes telencephalic outgrowth and regulates its rostral regionalization. FGF8 
dosage appears to mediate the size and nature of the neocortex as well as 
telencephalic midline structures and basal ganglia (62-66). Together, these data 
suggest that FGF signaling is important for processes that appear to be disrupted 
in 22q11DS such as the addition of outflow tract myocardium by 22q11-gene 
expressing cardiac neural crest cells from the secondary heart field and the 
organization of the developing forebrain.  
BMP’s 
In both the heart and the brain, BMPs and WNTs seem to co-ordinate 
proliferation and differentiation of progenitor cell populations (67, 68). Two 
important mediators of BMP signaling, Chordin and Noggin, are expressed in 
the dorsal endoderm and roofplate respectively (42, 69). Genetic ablation of 
Chordin alone, or in conjunction with Noggin, induces severe cardiovascular as 
well as cranial and spinal cord deficits in early gestation embryos (42). There is 
early expansion of the ventral mesoderm indicating the need for appropriate 
Bmp signaling for normal dorso-ventral patterning. The Chordin null lacks a 
thymus and parathyroid and has a hypoplastic thyroid (all derivative of the 3rd 
and 4rth pharyngeal pouch). In addition, the mutant exhibits persistent truncus 
arteriosus and do not form any of the pharyngeal arch arteries (42). Chordin; 
Noggin double mutant embryos lack extensive regions of the forebrain, as well 
as eyes, nasal placodes and facial structures. In addition, the telencephalon and 
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diencephalon are reduced to a small vesicle of thin neuroepithelium. In contrast, 
more posterior brain structures are relatively normal (70). Thus, appropriate 
antagonism and control of BMP signaling is required for the normal 
development of the forebrain as well as the pharyngeal structures that are 
disrupted in 22q11DS. 
22q11 genes: the search for a candidate 
Expression of 22q11 genes is spatially and temporally coincident with the 
activity of the 4 signaling networks described above. In order to understand the 
contribution of 22q11 genes to the complex network of cardinal-signal-driven 
development events, several mouse models have been generated, with each 
carrying deletions of varying lengths in the murine genome orthologous to the 
22q11.2 region in the human (LgDel(71); Df1(72); Figure 1). The defects in these 
mice closely recapitulate the cardiovascular phenotypes seen in human 22q11DS 
patients. Some of these vascular defects are partially rescued by crossing the 
LgDel mice with mice carrying 1-2 copies of artificial BAC’s containing 3-4 
human genes from the 22q11 region. Complementing the deletion with one 
particular BAC (BAC 316; Figure 1) containing Gnb1l, Tbx1, Septin5 and Cldn5 (2 
structural proteins, 1 transcription factor and 1 protein of unknown function) 
reduces the penetrance of vascular defects from ~45% to ~14%, indicating that 
these 4 genes are at least partially responsible for the cardiovascular defects seen 
in 22q11DS (71). Additional analysis of Tbx1 has shown localization to the 
pharyngeal epithelium. The varied penetrance (19%-43%) of pharyngeal arch 
defects in Tbx1+/- embryos has further implicated it in the development of 
cardiovascular defects (73). The lack of complete rescue by complementation 
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indicates that it is likely that additional genes within the 1.5Mb region contribute 
to the cardiovascular defects.  
To identify additional contributors to the phenotypes, several single-gene 
as well as contiguous gene knockouts have been made. Knockdown of another 
22q11 gene Dgcr6 results in cardiovascular defects in chicken (74) in addition to 
altering expression of multiple other 22q11 genes (Tbx1, Ufd1l and Hira --- genes 
potentially involved in cell cycle). Conditional ablation of a mitochondrial 
metabolic gene, Txnrd2, disrupts cardiomyocyte proliferation and results in fatal 
dilated cardiomyopathy (75). While several reports have claimed that Tbx1 alone 
is responsible for the heart phenotypes (71, 76, 77), closer examination of the 
above data and retrospective human genetic screens indicate that loss of Tbx1 
only partially contributes to the cardiovascular phenotype. Dgcr6, Txnrd2 and 
Ufd1L (and possibly Hira) potentially also contribute to the cardiovascular 
phenotype seen in 22q11DS by disrupting M/E signaling and associated cellular 
processes that are critical for pharyngeal morphogenesis. It is likely that 
disruption of many genes of varying function (cell cycle, transcription, 
metabolism, nucleic acid processing, structural) within the region disrupt 
signaling and morphogenesis to a greater degree than just one gene alone. Thus, 
diminished dosage of multiple 22q11 genes, such as but not limited to, Dgcr6, 
Txnrd2, Ufd1l, Tbx1 and Hira may disrupt cell-cell communication between the 
pharyngeal mesoderm and pharyngeal endoderm resulting in significant 
variability in development of the musculature, connective tissue and endothelial 
structures of the developing heart.  
It is likely that diminished dosage of one or more 22q11 genes disrupts 
neurogenesis, specification, differentiation or synaptogenesis leading to 
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structural as well as functional CNS deficits seen in 22q11DS. The search for 
genes contributing to the psychiatric phenotypes in 22q11DS has lead to a 
number of candidates, including Comt (a metabolic protein involved in the key 
pathways for the degradation of catecholamines), Dgcr8 (part of the micro-RNA 
processing complex), Prodh (proline metabolism), Rtn4r/NoGoR (a cell surface 
protein potentially involved in axon pathfinding) and Arvcf (Catenin family 
member involved in surface cell-cell interaction; potentially involved in Wnt 
signaling). Comt is a critical component of the pathway that degrades 
catecholamines including dopamine and epinephrine. Delayed or disrupted 
metabolism of these catacholamines from synapses could impair brain function 
due to elevated levels of these neurotransmitters (78). Dgcr8, is an integral part of 
a microprocessor machinery that is required for miRNA production and 
heterozygous loss leads to downregulation of a subset of mature miRNA’s (79). 
Diminished expression of a microRNA gene contained within the minimal 
deleted 22q11 region (mir-185) could have significant effects on the stability of 
target transcripts. While specific targets of mir-185 have not been established it is 
likely that altering miRNA levels during development due to deletion of Dgcr8 
and mir-185 could disrupt expression of developmentally critical genes and lead 
to disrupted cortical architecture and 22q11DS phenotypes. Diminished 
expression of Prodh, responsible for metabolism of L-proline, an amino acid that 
affects GABA-ergic neurotransmission, is responsible for increase levels of L-
proline found in about 50% of individuals with 22q11 deletion. Increased levels 
of this amino acid has been linked to epilepsy (80) and schizoaffective disorder 
(81, 82). Thus it is likely that diminished expression of Comt, Dgcr8, Prodh and 
several others within the 22q11.2 region (Txnrd2, Arvcf, NoGoR, mir-185) could 
	   14	  
significantly disrupt cortical circuitry and architecture leading to a high 
incidence of psychiatric disorders seen in 22q11DS patients. All these prior 
studies have taken the initial step of understanding the physiological 
contribution of some individual genes, but 22q11DS is the consequence of a 
multigenic deletion and must be studied as such. Understanding the 
developmental and physiological implications of a combined reduction in dosage 
of more than 30 genes will allow us to truly discern the molecular basis for 
22q11DS. Hence I will undertake a comprehensive analysis of the interaction of 
the 22q11.2 region and M/E signaling mechanisms that drive early 
morphogenetic events of the heart and brain. 
Interaction of signaling networks and 22q11 genes 
If multiple 22q11 genes and the cardinal M/E signals that pattern the 
forebrain and pharyngeal morphogenetic domains interact to facilitate 
appropriate cell-cell communication and in turn normal morphogenesis, then 
disrupting both should lead to new phenotypes not explained by additive effects 
alone. Appropriate morphogenesis of embryonic structures is regulated by the 
temporal and spatial integration of signals (BMP, SHH, RA and FGF) that 
modulate cellular proliferation, survival and fate. The secreted signaling 
molecules generated from a mosaic of patterning centers govern CNS as well as 
cardiovascular development. Most BMPs are expressed in the dorsal 
prosencephalon and dorsal endoderm (68), whereas SHH is ventromedially 
restricted in the brain and in the pharyngeal endoderm (83, 84), RA is expressed 
ventrolaterally in both regions (57) and FGF8 is expressed rostrally in the 
developing prosencephalon and in the endoderm adjacent to the precardiac 
mesoderm (85). These signaling molecules define dorsoventral and 
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anterioposterior axes. In addition, expression of inhibitors and receptors for each 
signal create a more complex mosaic of signaling within each morphogenetic 
domain. The existence of signaling centers in each structure where distinct 
regions express BMP, SHH, RA and FGF sets up an interactive signaling 
environment where the individual and combined actions of these cardinal 
signals drives appropriate morphogenesis. Thus, temporally altering this 
carefully controlled pattern of signaling in LgDel mice by ectopic administration 
of signaling agonists and antagonists will provide insight into developmental 
processes that rely on interactions between the deleted region and the altered 
M/E signal. 
Several studies in the developing brain, pharyngeal regions and limb (all 
regions affected in 22q11DS) indicate that there is significant interaction between 
these signaling pathways, (44, 86-90). In addition to interacting with each other, 
these signaling morphogens pattern expression of homeobox genes and 
important transcription factors in the developing brain and heart (44, 91). 
Overlap of phenotypes in signaling mutants and 22q11DS mouse models 
indicate that there might be interaction of 22q11 genes with in these signaling 
networks. Indeed, some initial evidence shows that several signaling molecules 
regulate expression levels and patterns of a 22q11 gene, Tbx1 (92) and that there 
might be some interaction between multiple 22q11 genes and developmental 
signals (93-96). Taken together, this data indicates that it is more appropriate to 
generate a comprehensive and integrative model of signaling gene networks and 
the role of 22q11 genes within them. My experiments will attempt to clarify the 
relationship between 22q11 genes and cardinal signals as either ‘downstream’ 
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(regulated by M/E signals) or ‘upstream’ (influencing M/E signaling) by 
delineate the regulatory as well as interactive nature of this relationship.  
Gene dosage: Morphogenetic thresholds and variability 
Congential heart and brain defects have significant variability that is not 
explained by total loss of one gene alone. 22q11DS accounts for 15% of patients 
with tetralogy of Fallot (TF), and over 50% of children with interrupted aortic 
arch (IAA) and truncus arteriosus (TA) (97). 22q11DS patients also account for 
8% of children with cleft palate, submucous cleft palate and occult submucous 
cleft palate (98, 99). There is also a high degree of overlap in phenotypes with 
other etiologically diverse multiple-anomaly genetic and epigenetic disorders 
(fetal alcohol syndrome (100), retinoic acid teratogenesis (101, 102), Downs 
syndrome (103), Rett syndrome (104), Noonan syndrome (105), Fragile X (106); 
Figure 4). While 22q11DS patients exhibit the full gamut of heart phenotypes, 
patients suffering from Fetal Alcohol Syndrome and Downs Syndrome exhibit 
TF and some septal defects while Noonan Syndrome patients have less severe 
septal defects and Fragile-X patients do not exhibit any abnormal phenotypes of 
the heart. Cognitive deficits in 22q11DS patients range from mild behavioral 
deficits to high incidence of ADHD, autism, mood disorders, and schizophrenia. 
None of the other single gene mutation or aneuploid diseases above have a high 
incidence of schizophrenia but share increased incidence of ADHD, autism and 
intellectual disability with 22q11DS. The partial penetrance and partial 
recapitulation of the phenotype in single gene mutants underscore the 
importance of studying 22q11DS and other multigenic diseases in a more 
integrated fashion. Understanding the molecular interaction between genes 
deleted in 22q11DS and cardinal signaling networks that drive early 
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morphogenesis of the structures affected in 22q11DS will shed light on potential 
etiology of similar defects that occur more commonly in the general population. 
Our multifaceted approach to studying these interactions has shown that 
22q11 genes are primarily expressed in mesenchymal tissue at sites of M/E 
interaction  (i.e the developing forebrain and pharyngeal arches) and that their 
expression is critically dependent upon Shh and to a lesser extent RA. 
Heterozygous loss of the entire 22q11.2 region, not just Tbx1 alone, specifically 
alters local levels of Shh and RA signaling. In addition we find that 22q11 genes 
establish a dynamic range of Shh and RA signaling variation within which 
morphogenesis can proceed normally. This range is constricted by 22q11 deletion 
leading to significant dysmorphogenesis of brain and pharyngeal structures in 
the face of signaling variation. Thus, our data suggests that morphogenesis of the 
brain and pharyngeal apparatus depends upon coordinate expression and 
interaction between 22q11 genes and signaling mediators in mesenchymal and 
epithelial tissues. Loss of 22q11 gene expression, primarily in the mesenchyme, 
likely alters the ability of this tissue to sustain appropriate morphogenesis in the 
face of signaling volatility leading to significant phenotypic variability in 
22q11DS patients. 
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 Figure 1: Gene map of the 22q11.2 region and its orthologous region on the 
mouse chromosome 16. 3Mb deletion is between LCR-A and LCR-D. Nested 
1.5MB deletion between LCR-A and LCR-B. Linkage of several individual genes 
to schizophrenia. LgDel mice have deletion of 26 genes. Df1 mouse has a nested 
21 gene deletion. BAC 316 used in complementation studies contains additional 
copies of 4 genes (indicated with a +). Individual mouse knockouts that have 
studied in the literature. 
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Figure 2: Mosaic of M/E signaling centers in the developing brain 
*Adapted from Ohkubo etal 2002 (44) and Tucker et al (107) 
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Figure 3: Formation of the arterial pole (A) Cardiac neural crest (purple – from 
rhombomeres 5/6) populate the second heart field. (B) Origin of the secondary 
heart field cells (purple) in the ventral pharynx (C) Myocardium (green) and 
smooth muscle (red) derived from the secondary heart field that form the arterial 
pole.  
 
*Adapted from Hutson and Kirby 2007 (108) 
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Autism 
(microdeletion) 
Down 
syndrome 
(Trisomy 21) 
VCFS 
(22q11 
microdeletion) 
Fragile X 
 (FMRP mutation) 
Rett syndrome 
(MECP2 mutation) 
Fetal Alcohol 
Syndrome 
      
  
  Jacquemont et al. 2006 dsahr.org cardiogenetics.org genetics.utah.edu rettsyndromealberta.org wikipedia.org 
 Estimated incidence 1:500 1:1000 1:4000 
1:4000 (male) – 
1:6000 (female) 
1:12,500  
(females) 1:750 
An
om
ail
es
 Cognitive Yes Yes Yes Yes Yes Yes 
Psychiatric Yes Alzheimers (~25% by age 35) 
Schizophrenia (25%) 
Autism (20%) Autism (~20%) 
Autistic-like 
Progresses to MR 
ADHD, Depression, 
others (90%) 
Craniofacial Yes Yes Yes Yes Yes Yes 
Cardiac Not noted Yes (VSD) Yes (VSD) Yes (Mitral Valve) Arrythmyias (No structural) Yes (VSD) 
Limb & digit Yes Yes Yes Yes Yes Yes 
 
 
Figure 4: Overlapping phenotypes of etiologically diverse genetic and epigenetic 
disorders 
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CHAPTER 2 
 
INTRODUCTION - II 
 
22q11 deletion syndrome (22q11DS), also known as DiGeorge or 
Velocardiofacial Syndrome, is the consequence of a hemizygous loss of a 
“critical” (1.5Mb) or larger “typical” (3MB) region of human Chr.22 (6, 109). 
22q11DS phenotypes, seen with variable penetrance, include life-threatening 
cardiovascular malformations (2, 10), craniofacial and limb abnormalities (110), 
parathyroid and thymic hypoplasia (111), and increased susceptibility to 
behavioral disorders and psychiatric diseases (112) suggesting altered brain 
development or function. Initial differentiation of most affected structures, 
including the brain and heart, depends upon mesenchymal/epithelial (M/E) 
interactions, mediated by signaling via Sonic Hedgehog (Shh), Fibroblast Growth 
Factors (Fgfs), Retinoic Acid (RA), and Bone Morphogenetic Proteins (Bmps) 
(113, 114). Loss-of-function mouse models for these M/E signals have 
phenotypes that overlap, to varying degrees, those in 22q11DS. Coincident 
expression and activity of 22q11 genes, Shh, Fgfs, RA and Bmps at M/E sites—
including the limb, face, heart and brain—suggest that normal signaling may be 
disrupted by altered 22q11 gene dosage (115). Nevertheless, it remains unknown 
whether 22q11 genes interact significantly with the cardinal M/E signals. Thus, 
we asked whether Shh, Fgf, RA, and Bmp signaling influences 22q11 gene 
expression and activity as well as whether diminished 22q11 gene dosage 
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modifies these signaling pathways during mid-gestation, when M/E signaling 
initiates significant morphogenesis at sites compromised in 22q11DS. 
Variable severity and penetrance of 22q11DS phenotypes suggests modifiers 
outside of the deleted 22q11 locus, and Shh, Fgfs, RA, Bmps, and related 
signaling molecules are likely candidates. Some phenotypes in mutant mice with 
disrupted Fgf8 (39) and RA (Raldh2)(40) signaling have been identified as 
22q11DS “phenocopies”, while Shh (41) and Noggin/Chordin (Bmp signaling) 
anomalies (42) are more narrowly interpreted as “parallel” to 22q11DS. It is 
unclear whether such similarities reflect convergence of signals and 22q11 genes 
consistent with “phenocopy”, or influence of 22q11 genes and M/E signals on 
distinct aspects of development in similar tissues. Shh and RA apparently 
regulate expression of at least one 22q11 gene, Tbx1 (92, 94) which when deleted 
in combination with Crkl (outside of the 1.5MB critical region, but within the 
broader 3MB “typical” region;(6, 116)) can modulate RA and Fgf8 signaling (93), 
while total loss of Tbx1 down-regulates Bmp4 (76). Moreover, recent observations 
suggest that additional genes outside the 22q11 minimal region modulate Tbx1 
mutant phenotypes (117, 118), some of which may be associated with RA (117) 
and Bmp (119) signaling. These observations, however, do not address 
interactions with 22q11 genes beyond Tbx1, which although critical, may not 
explain the full range of 22q11DS phenotypes (93, 115, 120, 121). Thus, we asked 
if M/E signals regulate 22q11 genes in the critical region; whether dosage of 
these genes influences Shh, Fgf, RA or Bmp signaling, and whether phenotypes 
in 22q11DS mouse models can be modified by altered inductive signaling. 
We found clear quantitative evidence of significant interaction between 22q11 
gene dosage and Shh as well as RA signaling pathways. Moreover, disrupted 
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Shh and RA signaling in mouse embryos with a deletion parallel to that in 
22q11DS results in significantly more severe phenotypes than altered signaling, 
22q11 deletion or heterozygous Tbx1 deletion alone. The reciprocal regulation 
and phenotypic modulation we have found does not support simple, linear, uni-
directional relationships between cardinal M/E signals and 22q11 genes; instead, 
they are likely part of a broader network that modifies distinct aspects of M/E-
mediated morphogenesis in the heart, brain and other phenotypic sites. This 
network may be an essential contributor to the phenotypic variability seen in 
22q11DS patients. 
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CHAPTER 3 
 
RESULTS 
 
Shh, BMP, FGF and RA signaling influence 22q11 gene expression 
 The 21 mouse orthologues of genes within the 22q11 critical region known to 
be selectively or specifically expressed at sites of M/E interaction (122) are 
selectively expressed in the mesenchymal compartment (Figure 5A; [21]). 
Analysis of the developing forebrain and branchial arches show that with the 
exception of 3 epithelium-restricted genes (3/21; Tbx1, Gnb1L and Slc25a1; Figure 
5A) the majority of 22q11 genes (18/21) are exclusively or selectively expressed 
in the mesenchyme. Heterozygous deletion of 28 contiguous murine 22q11 
orthologues (including 7 not expressed in the embryonic or adult brain, and thus 
not analyzed further here;(122)) in embryonic (E)10.5 LgDel embryos (71) results 
in a 50% expression decrement for each corresponding mRNA (Figure 5B), 
presumably primarily within the mesenchyme, where most of these genes are 
highly expressed. Thus, we asked whether altered Shh, RA, Fgf8, or Bmp 
signaling at E10.5, the peak age when each of these signals mediates M/E 
interactions at 22q11DS phenotypic sites—limbs, heart, face and forebrain—
disrupts expression of any 22q11 gene, perhaps to levels that seen following 
heterozygous deletion Dysmorphology and tissue loss complicates analysis at 
sites of M/E induction in Shh, Raldh2 (RA), Fgf8, or Noggin (Bmp) homozygous 
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mutant embryos. To circumvent this issue, we also manipulated each signal 
using pharmacological antagonists or agonists between E9.5 and E10.5. 
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Figure 5: 22q11 genes are expressed primarily in the mesenchyme at sites of M/E 
interaction, and are diminished by 50% by heterozygous deletion. (A) Tissue 
specific mRNA expression of twenty-one 22q11 genes in the epithelium and 
mesenchyme of the frontonasal mass (FnM; n=3). 11/17 detected genes are 
restricted to mesenchyme while 3 (grey shaded box) are restricted to the 
epithelium. The remaining 3 are expressed equally in mesenchyme and 
epithelium. (B) Tissue specific expression of the same 22q11 genes in Branchial 
Arch 1 (BA; n=3). Detection and tissue-specific expression mostly mirror that in 
the FnM; however, Dgcr1 is detected only in the BA mesenchyme while Arvcf is 
detected only in the FnM-mesenchyme. (C) Twenty-one 22q11 genes are 
expressed at 50±10% of wild-type levels following genetic heterozygous loss of 
22q11 genes in the LgDel embryo (n=3, p≤0.05; 2-tailed T-test). Mesenchymal or 
dual expressed genes indicated in black boxes with white letters; epithelial 
restricted genes are indicated in white boxes with black letters. 
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Shh regulation of 22q11 gene expression 
 Expression of ten of twenty-one highly expressed 22q11 genes was 
significantly altered by constitutive loss of Shh signaling in E10.5 Shh-/- embryos. 
Two of these ten are epithelially restricted (Figure 6A, thick outlined bars) while 
the remaining 8 are preferentially expressed in the mesenchyme. In mRNA 
samples from individual whole Shh-/- mutant embryos (n=4), seven of the ten 
genes that have altered expression are reduced to 50% of wild type levels (Figure 
6A, solid bars; comparisons based upon one way ANOVA for wild-type, LgDel, 
and Shh-/- embryos, p ≤0.05), paralleling that in the LgDel embryo (LgDel-like). 
Three additional genes are either reduced beyond 50% or significantly increased 
(Figure 6A, hatched bars; p ≤ 0.05). Of the seven genes that have LgDel-like 
expression changes, two are restricted to the epithelium (Figure 6A, thick 
outlined bars) and the other five are mesenchymal. Analysis of the Gli3Xtj/Xtj 
embryos (a presumed gain of Shh function;(45)) did not show reciprocal changes 
of 22q11 genes, Fgf8, or P75 (Figure 6B). 
 mRNA levels for epithelial (Fgf8; (85)) and mesenchymal markers (P75; (123)) 
are also significantly diminished in Shh-/- embryos, complicating interpretation of 
parallel diminished levels of 22q11 genes. Accordingly, to assess acute effects of 
Shh signaling, independent of concatenated morphogenetic disruption at M/E 
sites in Shh-/- embryos, we reduced Shh signaling between E9.5-E10.5 via 
maternal exposure to cyclopamine, which blocks Shh signal transduction (124) 
without the dysmorphogenesis seen in Shh-/- embryos. Brief, transient 
cyclopamine exposure results in a 50% reduction of Ptch1, a known Shh target 
gene (125) (Figure 6D); however, neither Fgf8 nor P75 are diminished. 
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Cyclopamine-dependent loss of Shh signaling also significantly alters expression 
of ten 22q11 genes. Eight of these ten genes are diminished by 50%, thus 
paralleling LgDel (Figure 6C; solid bars; p≤ 0.05), while an additional two are 
either increased, or reduced by less than 50%. Three of these eight genes are 
restricted to the epithelium (Figure 6C; solid yellow bars with thick outline), 
overlapping Shh expression domains. Five genes: Slc25a1, Dgcr6, Arvcf, Tbx1, and 
Septin5 are reduced to LgDel values in cyclopamine-treated as well as Shh-/- 
embryos.  
 We next assessed whether Shh signaling regulates 22q11 genes by 
maintaining normal expression levels or patterns using in situ hybridization 
(ISH) to analyze genes that substantially decrease or increase in response to 
genetic and pharmacological manipulation of Shh signaling. We evaluated Sept5, 
which is significantly diminished by both Shh-/- and cyclopamine, as well as 
Ranbp1, which is significantly increased by cyclopamine. For both genes, ISH 
labeling in cyclopamine-exposed embryos indicates diminished (Sept5) or 
enhanced (Ranbp1) levels, but not patterns of wild-type expression at sites of 
M/E induction (Figure 6E; n=4 for each probe). Thus, Shh signaling likely 
maintains normal levels, without apparent change in pattern, of a substantial 
subset of 22q11 genes in the mesenchyme and epithelium at 22q11DS phenotypic 
sites. 
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Figure 6:  Sonic hedgehog (Shh) signaling maintains normal levels of a 
substantial number of 22q11 genes. Epithelium-restricted 22q11 genes are 
indicated by thicker black outlines on bars. (A) Expression of ten 22q11 genes 
(yellow bars, hatched or solid) changes significantly in E10.5 Shh-/- embryos (n=4; 
p≤0.05; t-test); 7 of these changes are statistically equivalent to changes in the 
LgDel (solid yellow bars; p≥0.05; 2-way ANOVA) embryo. Significantly 
decreased expression of epithelial Fgf8 and mesenchymal P75 (black) suggests 
altered integrity of the respective tissues. (B) Minimal expression changes of 
22q11 genes in E10.5 Gli3-/- embryos (4/22 genes, hatched yellow bars); without 
significant changes in Fgf8 or P75 (open bars). (C) Transient cyclopamine-
induced inhibition (24-hr exposure; see Methods) of Shh signaling decreases 
expression of 10 22q11 genes (n=4, p≤ 0.05, t-test). Hatched bars indicate 
significant changes not equivalent to LgDel; 8 solid yellow bars are equivalent to 
LgDel (n=4; p≥0.05; 2-way ANOVA). Neither epithelial Fgf8 nor mesenchymal 
P75 expression is altered. (D) Ptch1, a known Shh target gene is downregulated 
to 50% of wild-type levels following 24-hr cyclopamine treatment (p≤0.05; n=4). 
(E) Changes in apparent intensity, but not pattern, of expression of Septin5 and 
Ranbp1 (largest magnitude changes) in response to 24-hr cyclopamine exposure 
shown by ISH in E10.5 embryos (n=5 for each probe). 
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RA signaling and regulation of 22q11 gene expression 
 
 Disrupted RA signaling in Raldh2-/- embryos (54) is accompanied by 
significantly decreased expression of sixteen 22q11 genes. Fifteen of these 
expression changes are statistically equivalent to changes seen in LgDel embryos 
(Figure 7A; solid bars; p ≤0.05). All but one gene is restricted to the mesenchyme, 
overlapping with domains of RA activity. These changes, however, are paralleled 
by significant expression changes of Fgf8 and P75 (50% and 200% respectively; 
Figure 7A), and likely reflect severe morphogenetic consequences, especially for 
mesenchyme, of constitutive loss of Raldh2 function at M/E sites (40). To 
circumvent interpretative difficulties due to likely tissue loss versus altered 
22q11 gene expression, we briefly enhanced or diminished RA signaling between 
E9.5 and 10.5 using all trans RA ((126); Figure 7B) and DEAB (an RA synthesis 
inhibitor; (127); Figure 7C), both of which alter expression of RA-regulated genes 
including Rarα (126), but do not significantly change Fgf8 or P75 (Figure 7B,C). 
RA significantly diminishes three genes—Ranbp1, Gnb1l, and Cdc45l—none, 
however, by 50% or more (Figure 7B, p ≤0.05). In contrast, RA increases Prodh 
and Septin5 (Figure 7B, 50-60%, p ≤0.05). These changes indicate that our sub-
teratogenic RA dosing regimen is the least disruptive of all our pharmacological 
manipulations. DEAB diminishes expression of six mesenchymal genes—Dgcr2, 
Dgcr6, Dgcr8, Septin5, Cldn5 and Hira—to LgDel levels (Figure 7C, p ≤0.05). ISH 
for Ranbp1 and Dgcr8, which are significantly decreased by RA and DEAB 
treatments respectively, indicates these changes reflect local fluctuations in 
expression level rather than pattern (Figure 7D,E). Apparently, RA signaling 
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modestly influences 22q11 gene expression levels at M/E inductive sites 
compromised in 22q11DS; however, there is no clear relationship between 
presumed increased (+RA) and decreased (Raldh2-/- or DEAB) signaling. 
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Figure 7: Altered RA signaling influences expression levels of a subset of 22q11 
genes. Epithelium-restricted 22q11 genes are indicated by thicker black outlines 
on bars. (A) Expression of 16 genes is significantly decreased in highly 
dysmorphic E10.5 Raldh2-/- embryos (n=4; p≤0.05; t-test); 15 of these changes are 
statistically equivalent to that in LgDel embryos (solid purple bars; p≥0.05; 2-way 
ANOVA); however, significantly altered Fgf8 and P75 expression (solid black 
bars) indicates disrupted epithelial and mesenchymal integrity. (B) 24-hr sub-
teratogenic RA exposure alters expression of 6 22q11 genes in E10.5 embryos 
(hatched purple bars; p≤0.05; n=4; t-test); however, none are statistically 
equivalent to that in LgDel embryos. (C) Transient inhibition of RA synthesis in 
E10.5 embryos using DEAB leads to diminished expression of six 22q11 genes to 
LgDel levels (solid purple bars). (D) Expression of the RA responsive gene, Rarα, 
is significantly increased following transient exposure of embryos to RA (50%) 
and DEAB (75%; p≤0.05, n=4 for each condition). (E) Expression of Septin5 is 
increased in the frontonasal mass, branchial arches and limb bud (solid white 
arrows) in response to 24-hr RA treatment; Dgcr8 expression in branchial arches, 
frontonasal mass and limb buds is decreased following DEAB mediated 
inhibition of RA synthesis (n=5 embryos/each probe). 
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Fgf and Bmp signaling and regulation of 22q11 gene expression 
 
 Fgf and Bmp signaling have less quantitatively detectable influence on 
maintaining normal levels of 22q11 gene expression at midgestation than either 
Shh or RA. In mildly dysmorphic Fgf8neo/neo embryos (approximately 40% of WT 
level of Fgf8; Figure 8A) a modest (approx.15%) but significant increase of Ranbp1 
is the only detectable 22q11 gene expression change (Figure 8A). PD173074 (128, 
129), a small molecule inhibitor of FGF receptor-mediated signaling, disrupts Fgf 
signaling at M/E sites, confirmed by the down-regulation of Mkp3 (130)). In 
PD173074-exposed embryos expression of seven 22q11 genes is significantly 
altered; five genes mirror LgDel changes, however, none parallel those in the 
Fgf8neo/neo embryos (Figure 8A,B). PD173074 also significantly diminishes Fgf8, 
with a similar trend for P75 suggesting potential tissue loss at M/E sites. ISH in 
PD173074-exposed embryos shows altered 22q11 gene expression levels at M/E 
sites (Figure 8F); nevertheless, there is also hypoplasia at M/E sites suggesting 
diminished tissue volumes not seen following 22q11 deletion (131). Thus, 
PD173074-induced 22q11 gene expression changes may be secondary, due to 
tissue loss. Together, this data indicates that the contribution of Fgf signaling to 
normal 22q11 gene expression levels is less direct and substantial than that via 
Shh or RA. 
 Enhanced Bmp signaling due to loss of Noggin mediated Bmp antagonism 
(Nog-/-(69)) significantly decreases one 22q11 gene (Txnrd2) by 50%, similar to 
LgDel (p≤0.05). Expression of 6 additional 22q11 genes is modestly (10-30%) but 
significantly diminished (p ≤0.05) without detectable change of Fgf8 or P75 
(Figure 8C). Inhibition of Bmp signaling by the small molecule antagonist 
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dorsomorphin (132) results in diminished expression of seven 22q11 genes, two 
of which are shared with Nog-/- embryos. Only three of the dorsomorphin-induce 
changes, however, are statistically similar to LgDel changes (Figure 8D), even 
though Id1 a known Bmp target is enhanced by 30% (Figure 8G). ISH in 
dorsomorphin-treated embryos is consistent with altered expression levels of 
Prodh, the most substantially diminished 22q11 gene, without significant changes 
in pattern or morphology (Figure 8H). Thus, the contributions of Bmp signaling 
to maintenance of normal 22q11 gene expression levels, judged by numbers of 
genes whose expression is significantly altered by disrupted Bmp signaling, 
appear less substantial than those of Shh and RA. 
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Figure 8: Fgf and Bmp signaling have limited impact on maintenance of normal 
levels of 22q11 gene expression. (A) Fgf8neo/neo embryos express 40% levels of 
wild-type Fgf8 (solid black bar), but have no LgDel-like changes in expression of 
22q11 genes; Ranbp1 is modestly but significantly increased. (B) Transient 
inhibition of FgfR mediated signaling reduces Fgf8 and P75 expression as well as 
eight 22q11 genes; 6 gene expression changes are equivalent to LgDel (solid red 
bars) while Prodh and Zdhhc8 display increased and greatly reduced expression, 
respectively (hatched red bars). (C) Noggin-/- embryos have no measurable 
changes in epithelial or mesenchymal markers, but display significant and 
modest decrements in 7 genes that are not equivalent to LgDel embryo dosage 
(hatched blue bars), with one exception, Txnrd2 (solid blue bar). (D) Transient 
pharmacological inhibition of Bmp signaling by dorsomorphin induces LgDel-
like decrements in Dgcr1, Arvcf, Tbx1 and Ufd1l (solid blue bars) as well as 
smaller magnitude changes in Prodh, Dgcr8, Comt, Septin5 and Hira (hatched blue 
bars). (E) Inhibition of FgfR signaling results in 55% reduced expression of the 
Fgf target gene Mkp3. (F) Septin5 expression is severely diminished in the 
developing forebrain, branchial arches and limb buds; structures that are also 
severely morphologically compromised. (G) Id1, a Bmp target gene is 
upregulated following 24-hr dorsomorphin treatment. (H) Prodh, quantitatively 
down regulated by dorsomorphin, is diminished in the developing forebrain and 
limb buds. 
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Diminished dosage of 22q11 genes disrupts M/E signaling pathway gene 
expression  
 
 There may be reciprocal regulation of 22q11 genes and cardinal M/E 
inductive signals including Shh, RA, Fgfs, and Bmps. If this were the case, 
diminished 22q11 gene dosage should alter ligand expression, availability, 
abundance or activity of receptors and signaling co-factors. Accordingly, we first 
asked whether diminished 22q11 gene dosage modifies Shh, Fgf, RA or Bmp 
signaling pathways. To evaluate such interactions, we first analyzed mRNA 
levels for Shh, Fgf, or Bmp ligands, RA synthetic enzymes, which are essential 
for ligand production, and key receptors, signaling co-factors, and metabolic 
regulators for each pathway in whole E10.5 LgDel embryos (71).  
 Three of the four M/E signaling pathways appear altered—all due to 
decreased, rather than enhanced expression—by varying degrees as a result of 
diminished 22q11 gene dosage in LgDel embryos. Two Shh transcriptional 
mediators, Gli1 and Gli3, decline in LgDel embryos (25%; p≤ 0.05; Figure 9A, far 
left). We detect no change in Shh ligands or receptors in whole embryo samples, 
including Ptch1 and Ptch2 which are unchanged despite known regulation by 
Shh-activated release of Gli transcriptional control (125, 133, 134). We next 
evaluated genes associated with RA synthesis, as well as RA receptors and co-
factors. Raldh3, an RA synthetic enzyme highly enriched in the brain (135, 136) is 
diminished by nearly 50% (p≤0.05; Figure 9A, left center). Two receptors, Rarα 
and Rarβ decrease by 28% and 19% respectively (p≤0.05). Crabp1, a binding 
protein thought to ensure ligand availability (137), declines by 30% (p≤0.05; n=4), 
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as does Cyp26a1, an RA degrading enzyme whose expression is RA-dependent 
(138) (p≤0.05, n=4). There were no changes in expression of two Fgf ligands, 2 
receptors, 3 signaling regulators and an established Fgf-regulated gene 
(Mkp3;(130)) in the LgDel embryo (Figure 9A, right center). Bmp ligands are not 
significantly altered; however, Id1 (a Bmp target gene) is modestly but 
significantly diminished (14%) as is the Bmp receptor BmpR1 (17%) and two 
transcriptional cofactors, Smad2 (16%), and Smad4 (26%; p≤0.05, n=4; Figure 9A, 
right). Thus, based upon analysis of representative molecular mediators of the 
four signaling pathways, we do not detect changes in Fgf signaling molecules, 
Shh and Bmp mediators change modestly, and the most frequent, substantial and 
statistically significant expression changes for multiple elements (ligand-related, 
receptors, and co-factors) in mid-gestation LgDel embryos are seen for RA 
signaling.  
Tbx1+/- and broader 22q11 deletion do not result in similar gene expression 
changes  
 Tbx1 has been proposed as a key, if not singularly explanatory, gene for 
several 22q11 phenotypes, especially those that reflect aberrant heart and brain 
development (71, 77, 139). If Tbx1 alone is responsible for the majority of 22q11 
phenotypes, and these phenotypes reflect altered Shh, RA, Bmp or Fgf signaling 
as suggested in several reports (93, 95, 96, 140), one would expect significant 
overlap between expression changes in Shh, RA or Bmp signaling molecules in 
LgDel and Tbx1+/- embryos. Of the 42 signaling intermediates we assessed, only 4 
are significantly altered in Tbx1+/- embryos (Figure 9B): 2 Shh signaling mediators 
(Smo and Sufu), and 2 RA-associated genes (Rarα, Raldh2). Of these four, only 
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Rara overlaps with changes in E10.5 LgDel embryos; however, the change is of 
smaller magnitude. One Fgf signaling intermediate, Spry4 (141) is altered in 
Tbx1+/- embryos, and no Bmp-related transcripts are changed (Figure 9B). Thus, 
there are fewer, and mostly divergent expression changes for M/E signaling 
pathway genes in LgDel versus Tbx1+/- embryos.  
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Figure 9: Divergent expression levels of M/E signaling genes—ligands or 
synthetic enzymes, receptors, transcriptional or metabolic cofactors—in LgDel 
and Tbx1+/- embryos. (A) Diminished expression of 2 Shh transcriptional co-
factors (Gli1 and Gli3), 5 RA synthetic enzymes, receptors or metabolic cofactors 
(Raldh3, Rarα, Rarβ, Cyp6a1, Crabp1 respectively) and 4 Bmp receptors, 
transcriptional co-factors or targets (Bmpr1, Smad2, Smad4 and Id1, respectively) 
in E10.5 LgDel embryos (p≤0.05; n=5; t-test). As a control, Hira, a 22q11 gene 
shows the expected 50% decrease. (B) Signaling gene expression in E10.5 Tbx1+/- 
embryos does not mirror LgDel changes. There is diminished expression of 2 Shh 
transcriptional co-factors (Smo and Sufu), 2 RA synthetic enzymes or receptors 
(Raldh2 and Rarα, respectively), and 1 Fgf transcriptional co-factor (Spry4; p≤0.05; 
n=4; t-test). As expected, Tbx1 expression is diminished by 50%. 
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Diminished 22q11 dosage results in altered Shh signaling at sites of M/E 
interaction 
Our initial screens suggest reciprocal interactions between Shh signaling and 
22q11 gene dosage may modulate M/E interactions and morphogenesis. To 
evaluate this hypothesis further, we measured the local “output” of M/E 
signaling via Shh at two clinically significant 22q11DS phenotypic sites, the heart 
and the forebrain, using either a “knock-in” (Ptch2:bGal;(142)) crossed into LgDel 
embryos to visualize and quantify local signaling independent of message levels, 
which may vary based upon stability and turnover. There are neither visible 
(Figure 10A) nor quantitatively detectable (Figure 10B) changes in Shh signaling 
in the head/forebrain of LgDel or Tbx1+/- embryos based on Ptch2:bgal 
transcription and activity. Shh signaling, however, apparently expands in the 1st 
and 2nd heart fields of LgDel embryos, and in parallel there is a 25% (p≤ 0.05, n=5) 
increase in soluble bgal activity (Figure 10A,B). Further analysis of local mRNA 
levels shows that Shh and its intermediates are unchanged in the head (Figure 
10C, and data not shown); however, Shh is increased by approximately 50% in 
the heart, and mRNA levels for a co-receptor Boc decline modestly. Similar 
changes are not seen in Tbx1+/- embryos (Figure 10D,E). Local measurements of 
Shh-related mRNA levels support this conclusion (Figure 10F, and data not 
shown). Thus, based upon observation and measurement in Ptch2 reporter 
embryos, and parallel assessment of local Shh-related gene expression, Shh 
signaling is altered in the heart of embryos carrying a deletion parallel to that in 
22q11DS patients. There may be changes in Shh signaling in Tbx1+/- embryos; 
however, they do not include altered Ptch2 activation or elevated Shh mRNA 
seen in LgDel embryos of similar age. 
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Figure 10: Shh signaling is increased in the developing heart in LgDel, but not 
Tbx1+/- E10.5 embryos. All embryos carry a β-galactosidase (β-gal) reporter under 
the control of the endogenous Ptch2 promoter. (A) Increased β-gal labeling in 
pharyngeal endoderm of LgDel (H/AA, bottom right) versus wild type embryos 
(bottom left; 8 LgDel and 10 wild type embryos analyzed). There is no apparent 
change in the forebrain/head. (B) Increased β-gal activity in the heart and aortic 
arches (H/AA) of the LgDel embryos, without change in the forebrain/head. (C) 
Increased Shh and decreased Boc expression in the heart and aortic arches 
(H/AA), but not in the forebrain/head. (D) No visible difference in cranial or 
cardiac β-gal labeling in wild type and Tbx1+/- E10.5 embryos. (E) Equivalent β-
gal activity in the head and heart (H/AA) of wild type and Tbx1+/- embryos. (F) 
There is no significant change in Shh or Boc expression in either head or heart 
(H/AA) of Tbx1+/- embryos. 
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Diminished 22q11 dosage results in altered RA signaling at sites of M/E 
interaction 
 To measure RA signaling activity we bred an RA-sensitive transgene in which 
βgal is expressed under the control of a DR5 retinoic acid response element 
(DR5-RARE; (57, 143, 144)) into the LgDel and Tbx1 lines. In LgDel embryos, DR5-
RARE-dependent RA signaling appears diminished, based upon intensity and 
extent of visible bgal labeling, in both the head/forebrain and heart (Figure 11A). 
In parallel, soluble bgal activity decreases modestly but significantly in the 
head/forebrain (12%; p ≤ 0.05, n=6) and heart (15%; p ≤ 0.05, n=6) of LgDel 
embryos (Figure 11B). Analysis of locally altered mRNA for RA receptors and 
signaling intermediates in microdissected E10.5 forebrain and heart is consistent 
with these changes. Rarb declines significantly in both the head/forebrain and 
heart of LgDel embryos (25-55%, Figure 11C; p≤ 0.05), as does the RA-synthetic 
enzyme, Raldh2, declines modestly (but not significantly) in the head, and more 
substantially in the heart (25% Figure 11C; p≤ 0.05). In contrast, in Tbx1+/- 
embryos, DR5-RARE expression, bgal activity and RA signaling mRNAs are not 
altered (Figure 11D-F). Apparently, RA signaling, at least that via DR5-RARE-
mediated responses, is diminished in the heart and head/forebrain of LgDel 
embryos with diminished 22q11 gene expression, but not with heterozygous 
Tbx1 deletion. 
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Figure 11: Diminished RA signaling in the head/brain and heart in LgDel, but 
not Tbx1+/- E10.5 embryos. All embryos analyzed express a β-gal reporter 
transgene expressed under the control of a RA responsive DR5-RARE. (A) 
Diminished β-gal staining in head (top right) and heart (bottom right) of E10.5 
LgDel versus wild type embryos. (B) Diminished enzymatic activity in 
microdissected LgDel head and heart (H/AA) compared to wild type. (C) LgDel 
embryos have diminished expression of Raldh2 and Rarβ in the heart (H/AA) but 
just Rarβ (solid purple bars) in the head (p≤0.05; n=6; t-test). (D) No differences in 
β-gal expression in the head or heart (H/AA) in Tbx1+/- versus wild type 
littermates. (E) β-gal activity is equivalent in Tbx1+/- and wild type littermates 
(n=4; t-test). (F) Expression levels of Raldh2 and Rarβ in the head and heart 
(H/AA) are equivalent in Tbx1+/- and wild type littermates. 
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22q11 gene dosage and Shh signaling interact during morphogenesis 
 If 22q11 gene function critically influences Shh participation in 
mesenchymal/epithelial (M/E) signaling, one would expect additive 
dysmorphogenesis and altered cellular differentiation at 22q11DS phenotypic 
sites if Shh signaling is compromised in LgDel. Alternately, if claims of 
phenocopy are accurate (41), one would expect phenotypic equality between 
LgDel and LgDel embryos in which Shh signaling has been disrupted. We first 
addressed this issue genetically by crossing Shh+/- with LgDel mice. Although 
some anomalies were seen, we recorded no consistent dysmorphology in F1 
littermates of the four possible genotypes (n=12 embryos; data not shown). To 
eliminate possible variation arising from alleles maintained on different genetic 
backgrounds (C57bl6:LgDel and S129:Shh+/-), we briefly diminished Shh signaling 
in LgDel litters between E8.5 and E10.5 using low doses of cyclopamine, 
previously determined to be non-teratogenic at E10.5 (See Figure 6). qPCR 
analysis of 22q11 genes showed that, apart from Zdhhc8, cyclopamine-mediated 
disruption of Shh signaling does not elicit additional changes of 22q11 gene 
expression beyond the 50% diminished dosage in untreated LgDel embryos 
(compare Figures 5 and 12A). Nevertheless, the consequences of diminished Shh 
signaling reliably distinguish wild type and LgDel littermates morphologically 
(Figure 12B). The most affected LgDel embryos fail to develop any identifiable 
non-axial structures (limb buds, aortic or branchial arches). In contrast, wild type 
embryos—even those most compromised by cyclopamine—have appropriate 
structures for mid-gestation embryos. Due to the broad range of dysmorphology 
in LgDel embryos, we selected the least phenotypic wild type and LgDel embryos 
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for qPCR expression analysis to minimize confounding effects of tissue loss. 
While Gli1 and Gli3 are modestly decreased in untreated LgDel embryos (see 
Figure 9), cyclopamine treatment results in substantially diminished levels of all 
Shh-related signaling genes measured in both wild type and LgDel embryos. 
While some decrements were more pronounced in the LgDel (Ptch1 - 79%, Smo - 
69%, and Gli1 - 61%; data not shown), the direction of change is uniform (Figure 
12C). Thus, diminished 22q11 gene dosage sensitizes the embryo to deleterious 
consequences of disrupted Shh signaling; however, this sensitization does not 
reflect further decreased 22q11 gene expression. 
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Figure 12: Diminished 22q11 gene dosage sensitizes embryos to altered Shh 
signaling. (A) qPCR shows no significant effect of 48 hour cyclopamine treatment 
on 22q11 gene expression in the E10.5 LgDel embryo. mRNA levels were 
measured in embryos with relatively milder phenotypes (see below). (B) Ptch2, 
Smo and Gli1 expression is similarly altered in LgDel and wild type littermates, 
indicating no significant effect of 22q11del on expression of these Shh signaling 
co-factors (2-way ANOVA). (C) LgDel embryos (top half) are more 
morphogenetically sensitive than wild type littermates (bottom half) to inhibition 
of Shh signaling by cyclopamine. Each embryo shown represents an apparent 
degree of phenotypic change (mildest, left; greatest, right), and numbers in 
parentheses indicate how many embryos were considered to be in each class, 
based on scoring by 2 independent observers, of 10 LgDel and 8 wild type 
embryos.  
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22q11 gene dosage and RA signaling interact during morphogenesis 
 If the proposed “phenocopy” (40) between 22q11DS and RA loss-of-function 
reflects a linear relationship where loss of 22q11 gene dosage results in 
aberrantly decreased RA signaling, then increasing RA signaling in LgDel 
embryos might rescue 22q11DS phenotypes. Thus, we asked whether modest 
elevation of RA via maternal circulation, (see Figure 7), mitigates phenotypic and 
gene expression differences between mid-gestation wild type and LgDel 
embryos. A transient increase of RA between E8.5 and E10.5 in LgDel embyros 
does not alter expression levels of mesenchymal or epithelial 22q11 genes beyond 
50% (Figure 13A); however, it does substantially disrupt cranial and 
cardiovascular morphogenesis of LgDel embryos compared to wildtype 
littermates (Figure 13B). LgDel embryos treated with RA exhibit significant 
defects in mesencephalic neural tube closure as well as 3rd and 4th pharyngeal 
arch artery morphogenesis (Figure 13B and 15B). LgDel embryos also display 
aberrant transcriptional responses at RA-signaling-related loci. Expression levels 
of Raldh1 and Raldh2, RA synthetic enzymes primarily expressed in the 
mesenchyme (136), are significantly diminished in the LgDel embryo (6- and 4-
fold, respectively; p ≤0.01) in response to increased RA availability (Figure 13C). 
This response is not seen in treated wild type or untreated LgDel embryos. Rarα 
and Rarβ are upregulated as expected in wild type embryos (6.8-fold and 2-fold, 
respectively) in response to increased RA (126); however, these genes are 
divergently regulated in RA-treated LgDel embryos (Figure 13C). Not only is RA 
unable to elevate Rarα in the LgDel—it diminishes Rarβ, a critical receptor for 
mesenchymal RA activity (145, 146)—a reversal of the wild-type response. A 
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two-way ANOVA, comparing expression of RA-responsive loci in wildtype, RA-
treated, 22q11 deleted or LgDel embryos treated with RA, confirms statistically 
significant interaction between the genetic deletion and acute pharmacological 
treatment with all-trans RA (p ≤0.001). Deletion of the DiGeorge critical region 
significantly affects tissue-response to variability in RA signaling, interfering 
with M/E signaling mediated morphogenesis of structures affected in DiGeorge 
syndrome between E8 and E10.5. 
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Figure 13: Diminished dosage of 22q11 genes sensitizes embryos to sub-
teratogenic RA exposure. (A) Increased RA availability between E8 and E10 does 
not have a significant effect on 22q11 gene expression in E10.5 LgDel embryos. (B) 
Distinct expression changes in RA signaling-related genes in LgDel embryos: 
Raldh1 and Raldh2 are significantly diminished in LgDel but not wild type 
littermate embryos in response to RA (p≤0.05; n=3; 2-way ANOVA). Rarα and 
Rarβ are increased in wild type, but not LgDel embryos (p≤0.05; n=3; 2-way 
ANOVA). (C) RA-exposed LgDel (top half) and wild type littermates (bottom 
half) have varying degrees of morphogenetic change in a sample of 15 LgDel and 
19 wild type littermate embryos from 4 litters scored by 2 independent observers. 
Representative phenotypic changes are shown for RA exposed LgDel embryos, 
and numbers in parentheses indicate frequency of each class We only noted mild 
dysmorphology (smaller size) in 2 wild type embryos 
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22q11del sensitizes cranial and cardiovascular morphogenesis to RA 
availability  
 If specific aspects of morphogenesis that are compromised at sites of M/E 
signaling in 22q11DS depend upon interactions that are sensitive to both 22q11 
gene dosage (115) and RA signaling levels (96, 126, 147), then modifying RA 
signaling in the LgDel embryo should result in specific additive or new 
phenotypes. Thus, we determined whether elevated RA results in consistent, 
distinct, intensified phenotypes in the brain or heart, sites of clinically significant 
developmental anomalies in 22q11DS (10, 148). A transient and sub-teratogenic 
increase in RA availability has a significantly different effect on LgDel embryos 
versus similarly treated wild type or Tbx1+/- embryos. 11 out of 15 (73%) LgDel 
embryos exposed to RA showed neural tube closure deficits at E10.5 (Figure 13B, 
Table 2). Exencephalic defects are seen in the posterior neural tube (1/15; 7%), 
rhombencephalon (4/15; 26%) and most frequently in the mesencephalon (6/15; 
40%; Figure 14A). Neither wild type nor Tbx1+/- littermates had any gross cranial 
phenotypes in response to increased RA availability. To evaluate potential cell 
biological consequences that accompany this gross morphological change, we 
assessed patterning, proliferative capacity and cytological integrity of wild type 
as well as RA-treated wild-type and LgDel forebrain precursors. We assessed 
localization of Nkx2.1 (ventral forebrain marker; Figure 14B) and Pax6 (dorsal 
forebrain marker), distribution and frequency of phospho-Histone3 (PH3, M-
phase precursors; Figure 14B), Nestin (radial glial/neural stem cells; Figure 14C), 
b-catenin (apical polarity; Figure 14D) and Tuj1 (early neurons; Figure 14E). 
Transiently increasing RA availability does not appear to disrupt dorso-ventral 
Nkx2.1/Pax6 patterning nor does it have a significant effect on proliferation of 
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forebrain progenitors based upon frequency of PH3 labeled cells. In addition, 
there were no detectable, LgDel-related disruptions of radial glial morphology, 
polarity or early neuronal differentiation in the nascent marginal zone. Thus, it is 
likely that the effect of altered RA availability on neural tube closure in the LgDel 
is due to either a proliferative change not measured by PH3 or a defect in 
progenitor cell patterning and identity that does not alter Pax6, Nkx2.1, Nestin, 
b-catenin and Tuj1. 
 We also analyzed 4th pharyngeal arch artery hypoplasia, a major clinical issue 
in a large subset of 22q11DS patients that is recapitulated with varying 
penetrance in several 22q11DS mouse models including LgDel mice, is (71, 73). If 
RA signaling interacts with 22q11 genes to direct pharyngeal arch artery (PAA) 
morphogenesis, then altering RA-signaling in the LgDel should further modify 
PAA development. As reported previously, 62% of untreated LgDel embryos 
display 4th pharyngeal arch defects (5/8, Table 2). There were no observable 
effects in the hearts of wild type embryos treated with RA (0/11, Figure 15A, 
Table 2). In contrast, increased RA availability in LgDel embryos increases the 
penetrance and severity of 4th arch defects to 100% (8/8, Figure 15B, Table 2), and 
intensifies LgDel 4th arch hypoplasia to complete lack of 4th arch development 
(5/8, Table 2). To assess if additive phenotypes reflect diminished dosage of Tbx1 
alone or additional 22q11 genes, we analyzed RA-treated Tbx1+/- embryos. 4/10 
(40%) untreated Tbx1+/- embryos had hypoplastic 4th PAA, consistent with 
previous reports (Figure 15C). Only 4/7 (57%) Tbx1+/- embryos treated with RA 
show 4th arch defects versus 100% of the RA/LgDel cohort (Table 2). In addition, 
while the most affected LgDel embryos have a highly dysplastic 3rd PAA and lack 
4th and 6th PAA, the most affected Tbx1+/- embryos have mildly dysplastic 3rd 
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PAA, lack 4th PAA but retain the 6th PAA (compare right panel of 10B and 10C). 
Deletion of the entire 22q11 critical region, including, but not of Tbx1 alone, 
clearly compromises cranial and cardiac morphogenesis by sensitizing the 
affected tissues to variation in RA signaling.  
  
	   62	  
 
 
  
!"#$% !"#$%&!"#$
%&'()*
+,-
%./012
3450.212
678*
!
"
#
$
%
	   63	  
Figure 14: Diminished dosage of 22q11 genes results in a higher frequency of 
exencephaly, without detectable changes in cellular organization of the forebrain 
neuroepithelium. (A) RA treatment has no noticeable effect on neural tube 
closure in E10.5 wild type embryos (left) but results in exencephaly in LgDel 
embryos (right; 73%, see Table1). (B) Nkx2.1 pattern and PH3 frequency (no 
statistical difference, data not shown) are not altered in the LgDel ventral 
forebrain following RA exposure. (C) Nestin staining of forebrain radial glia 
reveals no obvious difference in these presumed neural stem cells in the early 
forebrain. (D) Polarity of forebrain precursors (evaluated by b-catenin labeling) 
and (E) initial neuronal differentiation (Tuj1 labeling) are not noticeably 
disrupted by RA exposure. 
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Figure 15: RA exposure results in enhanced pharyngeal arch artery (PAA) 
dysmorphology in LgDel embryos. Confocal microscopic images of the 3rd, 4th 
and 6th PAAs of CD-31 (PECAM) antibody stained untreated (left panels) and RA 
treated (right panels) E10.5 wild type (A), LgDel (B) and Tbx1+/- (C) embryos. 
Yellow dotted lines indicate the outline of each PAA on the confocal Z-stack. 
Outline of PAA pattern, size and shape is shown to the right of the image. RA 
exposure has no significant effect on wild type embryos (compare left and right 
panels of A). Untreated LgDel embryos have the expected 4th PAA hypoplasia, 
while those treated with RA are severely dysmorphic (panel B, far right), 
exhibiting dysplastic 3rd PAA and absence of 4th and 6th PAAs. Tbx1+/- embryos 
treated with RA maintain development of the 3rd and 6th PAA but display 
dysplasia of the 4th PAA (far right, panel C). 
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CHAPTER 4 
DISCUSSION 
Reciprocal interaction between 22q11 genes and cardinal inductive signals—
especially Shh and RA—is crucial for normal gene expression, activity, and 
morphogenesis at sites of M/E interaction and phenotypic change in 22q11DS. 
Shh maintains normal expression levels of all epithelial and several 
mesenchymal 22q11 genes at these sites, while full dosage of mesenchymal 22q11 
genes establishes an appropriate context for production and activity of RA at 
sites of M/E interaction, especially the brain and heart. Diminished dosage of 
22q11 genes sensitizes the embryo to variations in Shh and RA signaling that 
would be aphenotypic in wild type embryos. Apparently, loss of 22q11 gene 
dosage constricts the range of Shh and RA signaling that is morphogenetically 
acceptable. Thus, by disrupting Shh and RA signaling, 22q11 deletion may lead 
to increased severity of brain and cardiovascular anomalies (149) due to 
decreased embryonic tolerance to signaling variability, potentially similar to 
naturally occurring signaling variation encountered during gestation (150).  
 
Shh maintains 22q11 gene expression 
An appropriate level of epithelial Shh signaling is needed to maintain normal 
expression of all epithelial and a significant number of mesenchymal 22q11 
genes. Constitutive or acute loss of Shh in Shh-/- and cyclopamine-treated 
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embryos, respectively, results in LgDel-like decrements of Slc25a1, Gnb1L and 
Tbx1 in the epithelium and Dgcr6, Ht9c, Arvcf, Septin5 and Hira in the 
mesenchyme; all are implicated in 22q11DS phenotypes (71, 121). In contrast, 
complete loss of Gli3 has no significant effect on levels of 22q11 genes, indicating 
that Shh-mediated maintenance of 22q11 gene expression levels is independent 
of Gli3. Homozygous loss of Hira (121) and Tbx1 (73) result in significant 
dysmorphology in the vasculature, heart or brain—paralleling, to some extent, 
phenotypes in Shh-/- (41). Several Shh-dependent processes, including skeletal 
development and vasculogenesis, are disrupted in 22q11DS. Thus, apparent 
similarities between 22q11DS and Shh loss of function phenotypes (40, 41) may 
be due to disrupted Gli3-independent Shh signaling that diminishes 22q11 gene 
expression to levels seen following 22q11 deletion.  
Decreased 22q11 gene dosage likely disrupts morphogenesis by altering Shh 
signaling levels. Expression of both Gli transcriptional effectors (Gli1) and 
activator/repressors (Gli3) are diminished in LgDel embryos. Nevertheless, Shh 
signaling output, as well as Shh expression, is increased in the heart based on our 
reporter as well as qPCR analysis in microdissected embryonic PAA/heart 
tissue. In the heart, it is possible that epithelial Shh, by maintaining 22q11 gene 
expression in the mesenchyme, sets up a feedback mechanism that further 
regulates epithelial Shh signaling centers (Figure 16A, (151)). Diminished dosage 
of Shh responsive 22q11 genes may disrupt this relationship leading to aberrant 
Shh expression, including the local increase in Shh expression we found in the 
heart (Figure 16B). Such local, potentially compensatory mechanisms may either 
serve to mitigate loss of 22q11 gene activity or further modulate M/E 
interactions required for appropriate morphogenesis. Recent studies have shown 
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that Shh is required for cardiac neural crest survival (46) and maintenance of 
heart field progenitor proliferation (47). Thus, the local gain in Shh activity we 
report here may defray some cardiovascular consequences of decreased gene 
dosage of Shh-regulated 22q11 genes like Hira and Tbx1 (92, 121, 152), while 
unchanged Shh signaling may actually place other phenotypic sites at greater 
morphogenetic risk (Figure 16B). 
 
RA signaling pathways are disrupted by 22q11 deletion 
Our data suggests that appropriate 22q11 gene dosage is required to maintain 
the integrity of retinoid signaling centers, most of which are located in the 
mesenchyme at 22q11DS phenotypic sites (138). Decreased expression in LgDel 
embryos of two RA-regulated receptors (Rarα and Rarβ(58, 153);) and a signaling 
cofactor (Crabp1), all known to be expressed primarily in mesenchyme (154), may 
interrupt RA production or activity at its mesenchymal sources (152, 155, 156) 
and disrupt RA signaling and metabolism in target tissues. Indeed, our indicator 
embryo assay shows that LgDel target tissues have significantly less DR5-RARE-
dependent transcription, an event often seen in epithelia adjacent to 
mesenchymal RA sources. Conversely, diminished 22q11 dosage may elicit 
ectopic RA-activity in the LgDel by decreasing expression of a metabolic P450 
enzyme that catabolizes RA in non-target tissues (Cyp26a1 (157);). Thus, deletion 
of multiple 22q11 genes critical to RA production or signaling in the 
mesenchyme may interfere with the ability of tissues to generate, transmit or 
metabolize RA resulting in locally decreased RA signaling output in the 
developing brain and heart (Figure 16B).  
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Appropriate levels of RA signaling are critical for patterning in the forebrain 
as well as pharyngeal arches and heart (152) (158, 159). Thus, the decreased RA 
signaling we identified in the head and heart of LgDel embryos may contribute to 
CNS and vascular defects in 22q11DS by disrupting numbers or distribution of 
RA-activated precursors (FIX REFS). Our data indicates that heterozygous 
deletion of multiple 22q11 genes but not Tbx1 alone alters RA signaling. If Tbx1 
was solely responsible for 22q11 phenotypes at sites of M/E induction—many of 
which are thought to reflect altered RA signaling (71, 95, 139)—one might expect 
significant or complete overlap between Tbx1+/- and LgDel embryos. With the 
exception of the epithelially expressed Rarα (145), there is no overlap of RA 
signaling gene expression changes in Tbx1+/- and LgDel mid-gestation embryos. 
Tbx1 deletion may result in RA signaling changes restricted to epithelial tissues 
while broader 22q11 deletion compromises both mesenchymal and epithelial 
compartments. Accordingly, deletion of the entire 22q11 region likely disrupts 
mesenchymal ability to generate, transmit and metabolize RA, leading to altered 
proliferation and differentiation in targets of local mesenchymal RA sources in 
the brain (160) and outflow tract (158, 161).  
 
Diminished 22q11 dosage sensitizes the embryo to altered signaling  
Our results indicate that full 22q11 gene dosage establishes a dynamic 
range of Shh and RA signaling within which morphogenesis proceeds normally 
(Figure 16A,B). Embryos with 50% dosage of 22q11 genes transiently challenged 
with cyclopamine or RA have significantly enhanced developmental anomalies 
not seen in their wild type littermates. CNS mid-line development, antero-
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posterior and dorso-ventral patterning as well as pharyngeal arch artery 
morphogenesis are critically dependent upon appropriate levels of Shh and RA 
signaling (55, 159, 162). Previous observations of dose-dependent increase in 
phenotypic severity in response to genetic (REF) or pharmacological 
manipulations of Shh and RA in wild type embryos suggest that modest 
variation may be tolerated; however, large changes disrupt development (124, 
148). In the face of signaling volatility, we have seen greater morphogenetic 
disruption in LgDel embryos than wild-type littermates. Thus, full 22q11 gene 
dosage may mediate adaptation to normal variation in Shh or RA signaling due 
to diet (163), drug or alcohol abuse (148) or toxic exposure (164, 165). Similarly, 
polymorphisms of Shh and RA-related genes in 22q11-deleted embryos might 
move signaling levels outside of optimal limits (Figure 16B), modifying the 
severity or penetrance of brain and cardiovascular phenotypes. Loss of 22q11 
gene dosage may preferentially alter the ability of the mesenchyme, where 22q11 
genes are selectively expressed, to buffer against signaling changes. Such 
changes can disrupt developmental capacity in both mesenchyme and 
epithelium leading to developmental aberrations in DiGeorge syndrome. 
The dynamic range of Shh signaling necessary for midline and non-axial 
development may be severely contracted by 22q11 deletion (Figure 16B; solid 
yellow). Total loss of Shh, critical for dorsoventral patterning and cell 
specification, results in severe midline deficits and heart developmental 
anomalies (48). Exposing LgDel litters to low levels of the Shh inhibitor 
cyclopamine during a critical stage for neural tube closure and dorsoventral 
patterning results in complete collapse of midline as well as non-axial 
development restricted to LgDel embryos. Thus, deletion of 22q11 genes leads to 
	   72	  
a contraction of the low end of the range of Shh signaling within which 
morphogenesis proceeds normally (Figure 16B). Additionally, increased Shh 
signaling output in the heart fields of LgDel embryos implies diminished 22q11 
gene dosage likely drives signaling to the low end of the dynamic range leading 
to a compensatory increase to maintain morphogenesis. This may contribute to 
incomplete penetrance of heart phenotypes in LgDel embryos (71). Exposing 
these embryos to cyclopamine in an attempt to rescue morphological deficits 
likely pushes them further outside the ‘dynamic range’ that can support normal 
development. Therefore, full 22q11 gene dosage buffers Shh signaling variability 
due to genetic or environmental causes by establishing a ‘dynamic range’ to 
preserve normal morphogenesis. 
Morphogenetic adaptability within a dynamic range of RA signaling also 
depends on 22q11 gene dosage. Aberrant, reversed transcriptional responses in 
LgDel embryos indicate that deletion of several upstream 22q11 genes disrupt 
downstream synthesis or transmission of RA. In the face of these RA signaling 
changes, LgDel embryos are unable to maintain the appropriate signaling range 
necessary for normal development. Abnormal expression decrements of 
synthetic enzymes (Raldh1 and Raldh2) and ineffective expression of receptor loci 
(Rara and Rarb) in the face of increased RA availability likely pushes the embryo 
past a threshold of morphogenetically acceptable RA signaling (Figure 16B; 
dotted line). Increased RA availability in RA-teratogenized and Cyp26a1 mutants 
(where RA variation is not efficiently modulated (59)) results in spina bifida, 
exencephaly and pericardial ballooning (59, 162). Parallel deficits in 
rhombencephalic neural tube closure and 3rd, 4th and 6th pharyngeal arch arteries 
in LgDel embryos in response to increased RA indicates that diminished dosage 
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of 22q11 genes, particularly in RA-producing and responsive mesenchyme, likely 
constricts RA dynamic range, disrupting RA-mediated brain and pharyngeal 
morphogenesis in the face of signaling volatility. Thus, our data indicates that 
multigenic 22q11 gene loss, not just Tbx1 alone, constricts the dynamic range of 
RA signaling within which embryogenesis can proceed normally. The loss of 
adaptability to RA signaling variation results in significant defects in neural tube 
closure and pharyngeal arch artery morphogenesis. 
 
A dynamic range for Shh and RA signaling and phenotypic variation in 
22q11DS  
One of the most defining characteristics of 22q11DS patients with either 
the minimal critical deletion or the larger typical deletion (149, 166), is the highly 
variable severity and penetrance of phenotypes (10). Comparisons of 22q11DS 
phenotypes to RA and Shh-related anomalies in humans and mouse-models 
suggest parallel or serial convergence of these pathways and morphogenesis of 
these structures (40, 41). It is likely that genetic polymorphisms or environmental 
insults that modify Shh or RA signaling may concatenate with the altered 
dynamic developmental range that we have described in the LgDel resulting in 
cell differentiation deficits in the forebrain as well patterning deficits in the 
second heart field. Several recent studies suggest that modifier loci associated 
with Shh and RA signaling may interact with DiGeorge genes (93, 95, 118). We 
have shown for the first time that likely causes for this variation are altered Shh 
and RA signaling due to diminished dosage 22q11 genes beyond Tbx1, and 
resulting divergent morphogenetic interactions at sites of M/E induction. Our 
data also indicates that a dynamic range of optimal Shh and RA-signaling may 
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be constricted in 22q11DS patients leading to phenotypic variation in response to 
changes in signaling that would normally not cause dysmorphology. 
Accordingly, allelic variation associated with Shh or RA signaling as well as 
early fetal exposure to Shh or RA agonists or antagonists such as oxysterols (167), 
ethanol (148) and glyphosate-based herbicides (168) in deleted individuals may 
modify heart, limb, face, or brain development. Thus, phenotypic variability in 
22q11DS may reflect the inability of M/E interactions to buffer stress of sudden 
or chronic changes in Shh and RA signaling engendered by additional genetic 
lesions or environmental stimuli. 
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Figure 16: Full 22q11 gene dosage supports, and diminished dosage constricts, a 
dynamic range of Shh and RA signaling. (A) Range of Shh (solid yellow) and RA 
(solid purple) signaling within which embryonic development proceeds 
normally in wild type embryos. Extreme signaling deviations (dotted yellow and 
purple) leads to disrupted morphogenesis (either side of dotted black lines). Shh 
maintains 22q11 gene expression (thick arrow), and full 22q11 gene dosage 
influences levels of Shh signaling (thin arrow). Normal dosage of 22q11 genes is 
required to maintain morphologenetically appropriate RA signaling (thick 
arrow) and RA availability modestly influences 22q11 expression (thin arrow). 
Wild type embryos develop normally since variable levels are “buffered” within 
an acceptable dynamic range (solid blocks) via 22q11 genes, even when 
challenged by cyclopamine (+Cyclopamine) and RA exposure (+RA). (B) LgDel 
embryos have contracted dynamic range within which morphogenesis proceeds 
normally (new boundary indicated by red dotted line; compare to black dotted 
line in panel A). Diminished 22q11 gene expression (smaller green box) increases 
Shh signaling (thick arrow-top right) and diminishes RA signaling (thinner 
arrow, lower right), particularly at sites of M/E interaction that are 
phenotypically compromised in 22q11DS. Disrupting Shh and RA signaling in 
LgDel embryos using identical sub-teratogenic dosages of cyclopamine and RA 
causes enhanced dysmorphogenesis in LgDel embryos because signaling levels 
fall outside of the constricted dynamic range. 
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MATERIAL AND METHODS 
 
Mice 
The University of North Carolina at Chapel Hill (UNC-CH) Division of 
Laboratory Animal Medicine maintained colonies of wild type Institute of 
Cancer Research (ICR), Shh+/-, Gli3+/-, Fgf8neo/+, Raldh2+/-, Nog+/-, Tbx1+/-, RA (DR5-
RARE-LacZ;(57)) and Shh-sensitive (Ptch2-LacZ, Deltagen) transgenic mice. All 
experimental procedures were reviewed and approved by the Institutional 
Animal Care and Use Committee at The University of North Carolina at Chapel 
Hill or the George Washington University School of Medicine. Mice carrying a 
heterozygous deletion in chr.16 from Idd to Hira were maintained on a C57BL/6J 
background (LgDel mice; (71)). In this study, the deletion was inherited 
paternally. Timed-pregnant litters (day of vaginal plug = E0.5) were generated 
by mating wild type mice, or mice heterozygous for each mutation, 
independently. Timed-pregnant females were sacrificed by rapid cervical 
dislocation and embryos were dissected and collected for RNA isolation, or fixed 
and appropriately processed for in situ hybridization, whole mount antibody or 
β-galactosidase substrate staining.  
Quantitative PCR (qPCR) 
E10.5 embryos were harvested, dissected and homogenized in TRIzol 
(Invitrogen). Total RNA was isolated per manufacturers instructions, and cDNA 
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synthesized as previously described (131). Power Sybr green reagent (Applied 
Biosystems), with 200 $M forward and reverse primer, was used to amplify and 
quantify specific transcripts from whole embryo or dissected regional cDNA 
samples using the ABI 7500 system (Applied Biosystems). 
 
Immunohistochemistry and In Situ Hybridization 
For immunohistochemistry and in situ hybridization, embryos were fixed 
overnight in 4% paraformaldehyde (PFA) in PBS at 4°C. Immunohistochemistry 
was performed on 20um cryostat sections as previously described (115). 
Immunofluorescently labeled sections were imaged using a Nikon 
epifluorescense (Eclipse 80i) microscope in combination with Surveyor© system 
(Objective Imaging). For whole mount immunofluorescent staining, embryos 
were serially dehydrated into methanol, stored overnight at -80°C, and freeze-
thawed five times. Following rehydration into PBS, specimens were incubated 
overnight at 4°C with gentle rocking in a blocking buffer comprised of 5% 
DMSO, 0.2% Triton X-100, and 5% normal goat serum, in PBS. Following 
incubation with primary antibodies (Rat anti-CD31; BD-Pharmingen) in blocking 
buffer overnight at 4°C, specimens were rinsed 5-6 times over an 8 hour period 
and subsequently labeled with Alexa-Fluor 488 or 546 conjugated anti-rat 
secondary antibodies overnight in blocking buffer at 4°C. Following further 
rinsing and dehydration into MeOH, samples were rendered optically 
transparent with a 2:1 solution of benzyl alcohol:benzyl benzoate (BABB) and 
imaged while in BABB in a custom chamber on a Zeiss LSM 510 confocal 
microscope. Z-Stacks were collected and 2D projections were created utilizing 
the Zeiss LSM image processing software. Primary antibodies were commercially 
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obtained [CD-31 (BD Pharmingen), PH3 (Cell Signaling Technology), Nestin 
(Millipore), Tuj1 (Covance), p-Smad (Cell Signaling Technology), b-catenin 
(Sigma), and Nkx2.1 (Santa Cruz)]. In situ hybridization was performed on 
whole-mount embryos as described previously (131) and these hybridized 
embryos were imaged on a Leica M420 macroscope. 
 
β-galactosidase staining and enzymatic activity quantification 
Embryos were harvested and dissected in ice cold PBS and either fixed in 0.1% 
glutaraldyhyde or lysed in 2X ONPG (ortho-Nitrophenyl-β-galactoside) lysis 
buffer (Promega ONPG assay system) for whole mount staining or a soluble β-
galactosidase activity assay, respectively. Whole mount fixed embryos were 
stained for β-galactosidase activity with X-gal substrate (Promega) as previously 
described (152). Head or heart tissue was dissected and solubilized in 2X lysis 
buffer (promega ONPG assay system) and total activity of β-galactosidase in the 
sample was detected as a function of enzymatic hydrolysis of ONPG into ortho-
nitrophenol. Samples were spectrophotometrically analyzed at 420nm on a 
ELX808 ultra microplate reader (Bio-Tek Instruments).   
 
Pharmacological treatment of embryos 
Pregnant wild-type dams were injected with 10mg/kg RA (Sigma), 100mg/kg 
DEAB (Sigma), 80mg/kg cyclopamine (LC Laboratories), 50 mg/kg PD173074 
(Sigma) or 10 mg/kg dorsomorphin (Sigma) at E9.5 and embryos were harvested 
24-hours later. Pregnant LgDel dams were injected with RA (10-20mg/kg) or 
cyclopamine (80mg/kg) twice (E8.5 and E9.5) prior to sacrifice on E10.5.  
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CONCLUSION 
 
Copy number variations are the most common type of structural 
variations in the human genome (169). There is increasing evidence of the role of 
CNVs in human disease. 22q11 deletion syndrome (22q11DS) is one of the most 
common “copy number variant” (CNV) genetic disorders currently known 
(1:2000) (4). The major phenotypes associated with 22q11DS, including 
cardiovascular and cognitive and behavioral deficits, indicates that early 
development of the brain and pharyngeal apparatus is affected (4, 9-11) due to 
diminished dosage of 22q11 genes. It is likely that the deletion specifically 
disrupts second heart field directed morphogenesis in the heart and 
compromises early patterning and differentiation of the telencephalon, leading to 
disrupted cortical circuitry in the brain (115, 170, 171). We examined the role of 
diminished dosage of 22q11 genes in M/E signaling mediated phenotypes. Our 
data supports the role for full dosage of 22q11 genes in maintaining a tissue 
microenvironment that is able to sustain normal morphogenesis even in the face 
of variable Shh and RA signaling. Deletion of the region and loss of 22q11 gene 
function in the cell cycle machinery, mitochondrial metabolism and microRNA 
processing likely interferes directly with RA signaling while disrupting Shh 
mediated morphogenesis in a parallel manner. 
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The Heart: 
Neural crest provides the mesenchyme for the 3rd, 4rth and 6th pharyngeal 
arches. The pharyngeal mesenchyme contributes first the myocardium and then 
the smooth muscle that forms the arterial pole (170). This region of the 
splanchnic mesoderm that forms the arterial pole is called the secondary heart 
field. As some of the secondary heart field progenitors differentiate, others 
continue to proliferate to generate enough cells to provide both myocardium and 
smooth muscle to the arterial pole (172). These proliferative cells are located 
more caudally in the field and are adjacent to the pharyngeal endoderm, which 
produces SHH (47). RA is synthesized and active in the anterior portion of this 
field. Thus it is likely that while Shh maintains proliferation, RA (in conjunction 
with other signals) provides differentiation signals to these progenitors.  
My data shows that 22q11 genes are mainly expressed in the mesenchyme 
of the pharyngeal pouches and brain, (except 3 that are restricted to the 
epithelium) and that heterozygous deletion results in 50% expression of all the 
genes. Diminished dosage of 22q11 genes also results in defects of the 
myocardium and the outflow tract, possibly due to altered proliferation or 
differentiation of second heart field cardiac precursors. Thus it is likely that 
diminished dosage of a subset of 22q11 genes (Ranbp1 (173), Cdc45l (174), Hira 
(175), Ufd1l (176) and Septin5 (177)), thought to modulate cell cycle may disrupt 
proliferation of the caudal second heart field progenitors resulting in a reduced 
contribution to the developing outflow tract. My data shows that Shh activity is 
necessary to maintain expression of all these cell-cycle genes except for Cdc45L. 
Another gene implicated in cell cycle regulation, Htf9c, is also dependent on Shh 
for expression. Thus, it is likely that the increased Shh transcript as well as 
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activity in the heart fields is a compensatory mechanism in response to loss of 
22q11 genes. Thus it is likely that diminished expression of these 22q11 genes 
associated with proliferation as well as several metabolic genes whose activity 
might support cell division result in decreased proliferation in the caudal second 
heart field and a compensatory increase in Shh signaling is necessitated to 
mitigate this effect. Supporting this hypothesis is my observation that decreasing 
Shh signaling in LgDel by administering cyclopamine between E8.5 and E10.5 
completely derails morphogenesis of the embryo. Thus it is likely that several cell 
cycle, structural and metabolic genes contained within the 22q11 region are 
involved in proliferation of caudal second heart field progenitors alongside SHH 
and the increase in Shh in LgDel is likely a compensatory mechanism to mitigate 
the drop in proliferation. It is important to investigate the cellular and molecular 
mechanisms that govern this interaction to better understand cardiovascular 
disease. 
 Once these second heart field cells have been generated in the caudal 
aspect of the secondary heart field they must migrate up toward the outflow 
structure and then differentiate into myocardial and smooth muscle structures. 
RA is a differentiation signal produced in the mesenchyme in the anterior part of 
the second heart field. In conjunction with TGFb signaling (including Bmp) it 
drives the specification, differentiation, septation and morphogenesis of the 
outflow tract (101, 158). My data shows that there is decreased RA signaling in 
the developing heart and aortic arch of LgDel mid-gestation embryos. It is likely 
that multiple 22q11 genes are involved in the transmission and response to the 
RA ligand. Increased RA availability disrupts pharyngeal arch artery patterning 
and alters outflow vessel morphogenesis and development. In addition, our data 
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shows that the response of the tissue to RA is significantly disrupted in the 
LgDel. I show that embryos with diminished dosage of 22q11 genes have a 
markedly different transcriptional response of RA-responsive loci when RA 
signaling is altered. My data also shows that RA may also regulate expression of 
a small subset of 22q11 genes (Dgcr6, Ranbp1, Dgcr8 and Septin5). Dgcr6 has 
putative functions as cell surface receptors and its loss results in cardiovascular 
defects. Interesting RA is required to inhibit expression of Ranbp1, a cell cycle 
related gene. It is likely that by inhibiting Ranbp1 (a gene positively regulated by 
Shh), RA could be shifting the proliferative nature of the progenitor cells to a 
more myocardial fate. Dgcr8 is part of a complex that processes microRNA and 
may have an important role in establishing cell identity. Septin5 being a 
structural protein could potentially be involved in changes in cell shape and 
structure and thus could have a role in cell differentiation driven by RA. Thus, it 
is likely that the microenvironment of the anterior secondary heart field where 
RA is actively involved in outflow tract differentiation is critically altered by 
diminished expression of a large set of 22q11 genes involved in establishing cell 
structure, cell cycle, cell metabolism and microRNA processing as a part of the 
RA signaling network.  
 Thus, our data indicates that, in the caudal secondary heart field, Shh-
dependent expression of a subset of 22q11 genes likely direct the proliferation of 
the progenitors that will eventually migrate into the anterior aspect of the 
secondary heart field where interactions between RA, BMP and several 22q11 
genes will drive the differentiation of these cells leading to outflow tract 
septation and morphogenesis. Future work should focus on an integrative 
approach to delineating the cellular and molecular roles of gene dosage within 
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these morphogenetic networks and the implications of gene dosage on 
establishing a genetic buffer for signaling variability. 
Brain: 
The cortex develops from a morphologically uniform ventricular zone 
located in the dorsocaudal part of the telencephalic vesicles. The development of 
the forebrain is governed by critical M/E interactions between signaling from the 
surface ectoderm, genes and signals expressed in the mesenchyme (mainly 
neural crest derived) and the developing neuroepithelium of the telencephalic 
vesicles. Regional identity and morphogenesis in the cortex is directed in part by 
Shh, Fgf, Bmp, Wnt and RA signaling centers producing secreted molecules. 
These centers are initially located along the edges and midline of the neural plate 
and later along and flanking the midline of the telencephalic vesicles (84, 178).  
Work in our lab suggests diminished dosage of a substantial set of 22q11 
genes expressed at sites of mesenchymal/epithelial interaction in the brain likely 
compromises early morphogenesis (122). Subsequently, diminished dosage in the 
LgDel mouse results in deficits in proliferation of the basal cortical progenitors 
and migration of newly-born interneurons into the cortex. These deficits lead to 
changes in the post natal brain such as decreased progeny of basal progenitor 
cells populating layer 2-4 of the cortex and altered laminar distribution of mature 
interneurons. We suggest that these defects could result from diminished dosage 
of a subset of 22q11 genes important for proliferation and migration (115). It is 
also likely that decreased expression of a subset of mitochondrial 22q11 genes 
involved in energy metabolism might compromise postnatal synaptogenesis. It is 
possible that modification of 22q11-dosage dependent development during 
initial forebrain patterning, later neurogenesis/ migration or post-natal 
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synaptogenesis may account for the variable behavioral pathology seen in 
22q11DS.  
While Shh, and to a lesser extent RA, maintain 22q11 gene expression, my 
analysis of early telecephalic stage embryos indicates that diminished dosage of 
22q11 genes results in decreased RA signaling in the brain, but does not have any 
significant effect on Shh signaling. Altering RA availability in the LgDel leads to 
lack of neural tube closure and exencephaly, reminiscent of RA teratogenesis. 
RA, synthesized in the neural crest derived mesenchyme, is a potent inducer of 
neuronal identity (156) and is required for early forebrain patterning and 
morphogenesis (179). Recent reports show that meningeal RA, which signals to 
the, is critical for the formation of the cortrex (56). Thus, diminished expression 
of cell-cycle and metabolic 22q11 genes, who likely play a role either in RA signal 
transduction and response or RA synthesis, likely alter the ability of lateral 
mesodermal tissue in the developing forebrain to synthesize/transmit RA, 
mispatterning forebrain progenitors. Additionally, diminished RA signaling in 
22q11DS likely disrupts the neurogenic gradient of RA necessary for appropriate 
corticogenesis later in development (56). 
Our analyses of E10.5 LgDel embryos that have been treated with RA do 
not show any overt changes in cellular identity, polarity or proliferation in the 
forebrain. It is likely that changes in early signaling might result in forebrain and 
cortical deficits later in development. Thus, the interaction of 22q11 genes with 
RA signaling should be studied on a molecular, cellular and anatomic level once 
the cortical plate has emerged.  
 It is likely that the constricted range of signaling that can support 
appropriate morphogenesis in 22q11DS patients likely explains the variability of 
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phenotypes seen in this disorder. Future studies need to investigate how the 
multigenic interaction between 22q11 genes and Shh and RA signaling networks, 
in the developing brain as well as secondary heart fields established this 
dynamic range. In particular, the inability to sustain normal development in the 
face of signaling volatility needs to be elucidated, as it will provide insights into 
phenotype variability in 22q11DS as well as other congenital anomalies that 
display variation in incidence and severity. Thus, my data supports the need for 
embryological screening of 22q11DS and concurrent evaluation of prenatal drug; 
diet ands supplementation in light of apparent increased developmental 
sensitivity in CNV compromised embryos. 
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